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ABSTRACT 
 
Triplex cell vaccine is a cancer immunopreventive cell vaccine that can 
prevent almost completely mammary tumor onset in HER-2/neu transgenic 
mice. 
A future translation of cancer immunoprevention from preclinical to clinical 
studies should take into account several aspects. The work reported in this 
thesis deals with the study of three of these aspects: vaccine schedule, activity 
in a therapeutic set-up and second-generation DNA vaccines. 
An important element in determining human acceptance and compliance of a 
treatment protocol is the number of vaccinations. In order to improve the 
vaccination schedule a minimal protocol was searched, i.e. a schedule 
consisting of a lower number of administrations than standard protocol but with 
a similar efficacy. A candidate optimal protocol was identified by the use of an 
in silico model, SimTriplex simulator. The in vivo test of this schedule in  
HER-2/neu transgenic mice only partially confirmed in silico predictions. This 
result shows that in silico models have the potential ability to aid in searching 
of optimal treatment protocols, provided that they will be further tuned on 
experimental data. As a further result this preclinical study highlighted that 
kinetic of antibody response plays a major role in determining cancer 
prevention, leading to the hypothesis of a threshold that must be reached 
rapidly and maintained lifetime. 
Early clinical trials would be performed in a therapeutic, rather than 
preventive, setting. Thus, the activity of Triplex vaccine was investigated 
against experimental lung metastases in HER-2/neu transgenic mice in order to 
evaluate if the immunopreventive Triplex vaccine could be effective also 
against a pre-existing tumor mass. This preclinical model of aggressive 
metastatic development showed that the vaccine was an efficient treatment also 
for the cure of micrometastases. However the immune mechanisms activated 
 10 
against tumor mass were not antibody dependent, i.e. different from those 
preventing the onset of primary mammary carcinoma.  
DNA vaccines could be more easily used than cellular ones. A second 
generation of Triplex vaccine based on DNA plasmids was evaluated in an 
aggressive preclinical model (BALBp53neu female mice) and compared with 
the preventive ability of cellular Triplex vaccine. It was observed that Triplex 
DNA vaccine was as effective as Triplex cell vaccine, exploiting a more 
restricted immune stimulation. 
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CANCER IMMUNOPREVENTION 
 
The immune surveillance theory, that was proved both in animal models and 
human studies, states that the immune system is physiologically active in the 
prevention of spontaneous tumors. On the contrary, several decades of attempts 
to further stimulate antitumor immunity for therapeutic approaches have given 
poor results. The better efficiency of immune system in preventing rather than 
cure tumors has led, in recent years, tumor immunologists to suggest that the 
immune system, if adequately stimulated before tumor onset, could be able to 
protect the organism from specific cancers (Lollini et al., 2006a). 
An obvious approach consists in prevention of tumors related to infectious 
agents, such as human hepatitis B virus (HBV) and human papilloma virus 
(HPV), closely related to liver and cervical carcinoma respectively. In fact, 
vaccination against HBV has reduced the incidence of hepatocellular 
carcinoma, whereas vaccines against HPV are expected to greatly reduce the 
incidence of cervical carcinoma. A less obvious approach deals with the 
immunoprevention of tumors caused by endogenous factors. Vaccines targeting 
these factors could be a new promising approach in order to control endogenous 
molecules and protect from tumor development. Another approach to control 
tumor onset could be chemoprevention, consisting of chronic administrations of 
drugs targeting components of metabolic or signaling pathways, such as 
tamoxifen to reduce the risk of breast cancer. The limits of chemoprevention 
are the partial efficacy and the serious side effects. Cancer immunopreventive 
approaches, such as vaccines, could reduce the amount of side effects thanks to 
the selective action and probably could require less invasive procedures (Lollini 
et al., 2006a). 
Cancer immunoprevention has insofar produced good results in preclinical 
studies, although it is still far from the clinic and several questions need to be 
answered before progressing into clinical trials (Lollini et al., 2006a).  
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The choice of a right target is an important issue to develop an effective 
vaccine. Up to now many tumor antigens have been described, but only a few 
molecules proved to be good target antigens for cancer immunoprevention. 
Tumor associated molecules that are essential for tumor growth and progression 
could be suitable cancer vaccine targets, since they cannot be easily 
downmodulated or negatively selected in precancerous lesions under the 
pressure of a specific immune attack. Lollini and colleagues have defined these 
molecules as oncoantigens (Lollini et al., 2006a). Oncoantigens should be 
poorly expressed by normal adult tissues, but overexpressed by tumor (Cavallo 
et al., 2007). Moreover the presence of target antigens on the cell membrane 
seems to be an optimal condition to obtain both a cell-mediated and an 
antibody-mediated immune response. Molecules eligible to be defined as 
oncoantigens include tyrosine kinase receptors, such as the epidermal growth 
factor receptor (EGFR), the insulin-like growth factor-1 receptor (IGF1R) and 
the vascular endothelial growth factor receptor (VEGFR). Other potential 
oncoantigens could be receptors of B- and T- cells. Adhesion and surface 
molecules involved in survival, invasion and malignancy could be part of 
oncoantigen class as well (Lollini et al., 2005b).  
The development of cancer vaccines should progress through different 
phases and one of the first steps is the validation of the vaccine in appropriate 
animal models (Wei et al., 2008). Preclinical studies on antitumor vaccines are 
usually based on the evaluation of vaccine efficacy leading to the acute 
rejection of a subsequent tumor challenge. A more realistic alternative consists 
of models which develop autochthonous tumors induced by carcinogens or by 
genome manipulation. Genetically engineered mice (GEMs), harboring 
activated oncogenes and/or inactivated tumor-suppressor genes, are prone to 
develop cancer by molecular and genetic alterations that could resemble the 
stepwise progression of human cancer (Quaglino et al., 2008). GEMs are 
interesting models for cancer prevention thanks to the slow tumor progression, 
generally comprising invasion and metastasis, and to the presence of a long-
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lasting interaction between the evolving tumor and the host immune system. 
Two main relevant issues in the choice of a model are the type of promoter, that 
will drive the pattern of transgene expression, and the existence (and eventually 
breakage) of immune tolerance to transgene-encoded proteins, in analogy to 
what happens for most tumor antigens in humans (Lollini et al., 2006a). 
Vaccines consisting of live, irradiated or genetically modified tumor cells, 
dendritic cells, proteins, peptides or naked DNA have been tested in GEMs. 
The degree of protection varies among models and within the same model, 
ranging from delayed tumor onset to complete protection from tumor onset for 
one year or more. The most successful vaccines in preclinical studies consisted 
of combinations of the target tumor antigen with other immunological signals 
acting as adjuvants, such as microbial CpG sequences, cytokines, allogeneic 
glycoproteins of the major histocompatibility complex (MHC) and/or co-
stimulatory molecules. On the whole the efficacy of a tumor preventive vaccine 
depends both on a high level of the antigen and on the adjuvants. Tumor 
antigens, both in humans and GEMs, are mostly self-antigens overexpressed by 
tumor. Adjuvant molecules, inducing an aspecific immune response, contribute 
to break the immune tolerance to tumor antigens. Therefore the efficacy of a 
vaccine is based on its ability to reverse a tolerant state and activate low-avidity 
immune reaction mechanisms that escape the central tolerance (Lollini et al., 
2006a). 
Concerning the immune mechanisms induced by immunopreventive 
vaccines, a coordinate induction of T-helper cells, cytotoxic T lymphocytes 
and, above all, antibodies seems to determine vaccine protective ability in 
preclinical models. In order to ensure a long-term immune response, vaccines 
should be able to elicit immune memory mechanisms that are believed to 
persist for a very long period. This could only be possible by repeated boost 
vaccinations (Lollini et al., 2006a). 
Besides immunopreventive approaches such as vaccines, other cancer 
immunopreventive strategies include passive administration of antibodies 
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against surface oncoproteins, such as trastuzumab, and active stimulation of 
immune system by non-specific immunomodulators, such as interleukin (IL-) 
12 or bacterial products (Lollini et al., 2005a).  
Among target tumor antigens for cancer immunopreventive strategies the 
human epidermal growth factor receptor 2 (referred to as HER-2 or ErbB2) is 
one of the widely studied. This receptor can lead to neoplastic transformation, it 
is overexpressed in a fraction of human breast cancers and is a surface 
molecule. Such features permit to include HER-2 in the class of oncoantigens 
(Lollini et al., 2005b). 
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CANCER IMMUNOPREVENTION IN HER-2/neu 
TRANSGENIC MICE 
 
HER-2 
HER-2/ErbB2 is a member of the human epidermal growth factor receptor 
family of tyrosine kinases which includes EGFR/ErbB1, HER-3/ErbB3 and 
HER-4/ErbB4. The general structure of these molecules consists of an 
extracellular ligand-binding domain, a single-span transmembrane domain and 
an intracellular domain that contains the conserved catalytic-kinase domain and 
the carboxy-terminal tail (Figure I) (Sergina and Moasser, 2007). The rodent 
homologue of HER-2 is the oncogene neu. The product of HER-2/neu genes is 
a protein of 185 KDa (p185). 
Figure I. Structure of the HER-2 and neu 
proteins. The domain structure is shown on the 
left and consists of two ligand-binding regions 
(LD1 and LD2), two cysteine-rich regions 
(CR1 and CR2), a short transmembrane 
domain (TM), a catalytic tyrosine kinase 
domain (TK) and a carboxy terminal tail (CT). 
Sites of tyrosine phosphorylation within TK 
and CT domains are indicated by circled P. 
The letters on the right point to specific areas 
that are altered or mutated in certain naturally 
occurring or experimentally induced cancers 
(Moasser, 2007b). 
 
 
 
The signaling cascade is initiated by the ligand-mediated interaction of two 
HER family members. The extracellular domain of HER proteins has two 
conformations: closed when inhibited and open when activated. Ligands 
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promote a change of the extracellular domain structure and then dimerization of 
two HER family members. Finally the transphosphorylation of their 
intracellular domains causes the activation of several downstream pathways. 
Pairing between HER proteins seems to be closely connected to several and 
specific signaling activities. Heterodimers are favorite over homodimers and 
HER-2 has the strongest catalytic kinase activity, therefore HER-2-containing 
heterodimers have the most powerful signaling functions. In detail, HER-2 and 
HER-3 form the most active complex of the family, although both of them are 
functionally incomplete receptor molecules. In fact HER-2 extracellular domain 
constitutively presents only the activated conformation since the receptor lacks 
ligand-binding activity and its signaling function is engaged by its ligand-bound 
heterodimeric partners. HER-3 catalytic domain is constitutively inactive thus 
HER-3 exploits the kinase domain of its partners (Moasser, 2007b). 
The HER family controls a comprehensive network of survival, growth, 
metabolism and motility responses by activation of several signaling pathways 
as phosphoinositide 3-kinase (PI3K)/Akt, Raf/mitogen-activated protein kinase 
kinase (MEK)/mitogen-activated protein kinase (MAPK), Janus kinase 
(JAK)/signal transducer and activator of transcription-3 (STAT-3), Src, 
phospholipase C-γ (PLC γ) (Sergina and Moasser, 2007). 
HER-2 is involved in the development of human cancers: 25-30% of breast 
cancers show HER-2 gene amplification and overexpression of its product. 
HER-2 overexpression is a predictor of mammary tumors with a worse biologic 
behavior and prognosis (Slamon et al., 1989). Moreover HER-2 protein 
overproduction is found in cancers of esophagus, stomach, ovaries and 
endometrium. Evidences suggest that HER-2 amplification is an early event in 
human breast tumorigenesis. HER-2 amplified breast cancers are more 
responsive to some cytotoxic chemotherapeutic agents, show resistance to some 
hormonal agents and have an increased propensity to metastasize to the brain. 
Somatic mutations within HER-2 catalytic domain have been described in a 
small subset of lung cancers (see Figure I, D); this genetic alteration promotes 
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an increased kinase activity and transforming efficacy. Siegel and colleagues 
(Siegel et al., 1999), and Castiglioni and colleagues (Castiglioni et al., 2006) 
reported data on an alternative HER-2 transcript. The lack of a 48 bp coding 
exon and consequently a 16 aminoacids deletion from juxtamembrane region 
(see Figure I, B), produces an alternative HER-2 protein (∆HER-2) with a 
higher ligand-independent signaling activity and transforming potency 
(Moasser, 2007b).  
The role of the different HER-2 related pathways in tumor development is 
not completely defined. Surely HER-2 overexpression leads to an increase of 
HER-2 homodimers and heterodimers. Such increased number of complexes 
promotes the loss of polarity and a deregulation of cell adhesion. Moreover 
downstream signals such as PIK3, β4 integrin, src, and others, contribute to an 
invasive phenotype. A few number of studies reported an upregulation of cyclin 
D1, E and cdk6 and degradation of p27 in HER-2 overexpressing tumors. Thus, 
HER-2 overexpression produces a change in proliferative, survival, invasive 
and metabolic functions. Some authors also proposed a role in carcinogenesis 
for genes amplified with HER-2 as neighbors, for molecules considered 
transcriptional targets of HER-2, for the membrane protein MUC4 and for other 
pathways (Moasser, 2007b). 
Since HER-2 is directly involved in tumor pathogenesis, it is a prototypic 
oncoantigen and HER-2 inhibitors should be highly effective treatments for 
HER-2-driven cancers. The most successfully developed drug is a humanized 
anti-HER-2 monoclonal antibody named trastuzumab. Several clinical studies 
showed that this drug, developed and commercialized by Genetech Inc. as 
Herceptin (South San Francisco, CA, USA), induces improvements in the 
clinical management of patients with HER-2-amplified breast cancer. The most 
beneficial clinical use of trastuzumab has been in combination with various 
cytotoxic chemotherapies. The biggest impact of this drug has been in the 
treatment of patients with potentially curable early-stage breast cancer since 
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this drug prolongs disease survival, after surgical resection, and reduces the 
chances of disease-free recurrence (Moasser, 2007a). Trastuzumab kills tumor 
cells through multiple mechanisms whose relative importance is not yet 
definitively established. The interaction of this drug with immune system by 
antibody-dependent cellular cytotoxicity (ADCC) is proved (Weinberg, 2007). 
Concerning other mechanisms, the study of trastuzumab effect on tumor cell 
HER-2 expression has produced conflicting results (Moasser, 2007a). It is 
known that trastuzumab inhibits the cleavage of a part of HER-2 extracellular 
domain by extracellular proteases reducing the formation of truncated HER-2 
that has an increased transforming efficiency. Finally trastuzumab can show an 
anti-angiogenic activity (Weinberg, 2007). Other drugs have been developed 
and they are being tested in clinics such as anti-HER-2 monoclonal antibody 
pertuzumab and HER kinase inhibitors (Moasser, 2007a).  
 
HER-2/neu TRANSGENIC MICE 
HER-2/neu transgenic mice are likely the most extensively studied models 
for the evaluation of immunopreventive approaches against mammary cancer. 
These models, developed in the last 20 years, comprise various transgenic 
mouse lines differing in the genetic background (FVB, BALB/c, CD-1), the 
type of promoter, the type of oncogene and the species of origin (Ursini-Siegel 
et al., 2007).  
The most popular promoters were the long terminal repeats (LTR) of the 
mouse mammary tumor virus (MMTV) and the promoter of the whey acidic 
protein (WAP). These two promoters induce a high level expression of the 
oncogene specifically in the mammary epithelium. Both MMTV-LTR and 
WAP promoters are hormonally sensitive promoters. The MMTV-LTR is 
active throughout mammary development and its transcriptional activity 
increases during pregnancy. On the contrary, the WAP promoter is only active 
in the mid-pregnant mammary gland. Consequently it is evident that the 
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phenotypes exhibited by WAP and MMTV transgenic mice may depend upon 
the developmental stage of the individual mouse examined. Few models 
express the transgene under the control of the endogenous promoter 
(Hutchinson and Muller, 2000). 
For what concerns the type and the origin of HER-2/neu oncogene, several 
mouse models were developed. The rat neu oncogene can transform mammary 
epithelial cells in vitro and transforming activity is caused by a point mutation 
within the transmembrane domain (see Figure I, C) producing the V664E-
mutated protein named neuT. This mutation promotes receptor dimerization 
and enhances the tyrosine kinase activity. The activated neu oncogene (neuT) 
expressed in mouse mammary tissue induces adenocarcinomas. The c-neu 
protooncogene, when overexpressed in murine mammary tissue, also induces 
tumor formation, but this mainly occurs through acquirement of deletion 
mutations within the extracellular juxtamembrane region that promote 
dimerization and enhanced kinase activity (see Figure I, A). Other mouse 
models were developed using human wild-type HER-2 or mutated HER-2 
V659, although this genetic alteration was never found in human cancers 
(Moasser, 2007b). 
HER-2 transgenic mice have been used for studies of cancer 
immunopreventive approaches in the Laboratory of “Immunology and Biology 
of Metastasis” (Cancer Research Section, Experimental Pathology Department) 
directed by Prof. Pier-Luigi Lollini. Hereafter the main characteristics of these 
HER-2 transgenic mice will be summarized. 
 
BALBneuT 
BALBneuT female mice have the genetic background of BALB/c mice and 
carry the rat neu activated oncogene under the control of the MMTV promoter 
(Boggio et al., 1998).  
 20 
BALBneuT female mice develop multifocal mammary carcinomas with a 
short latency, about 20 weeks of age. Within 33 weeks of age lobular 
carcinomas are palpable in all 10 mammary glands. This rapid onset and the 
total gland involvement suggest that the expression of activated HER-2/neu in 
these mice requires few, if any, additional genetic events to transform the 
mammary epithelial cells (Boggio et al., 1998).  
Mammary carcinogenesis in BALBneuT mice resembles the mains aspects of 
human breast carcinomas. Starting at 3 weeks of age, an atypical hyperplasia of 
small lobular ducts and lobules is evident and epithelial cells show expression 
of p185neu. These proliferating areas progress to carcinoma in situ at about 11 
weeks of age and then the neoplastic regions evolve in lobular carcinomas, 
macroscopically evident around 20 weeks of age. Tumor formation proceeds 
independently and multifocally in all ten mammary glands and, later, gives rise 
to metastases detectable in the lungs. Single metastatic cells are already present 
in the lung and bone marrow at time of non-invasive atypical hyperplasia (Di 
Carlo et al., 1999; Husemann et al., 2008). 
 
BALBp53neu 
BALBp53neu mice are bigenic mice obtained by crossing BALBneuT mice 
with BALB/c mice with heterozygos p53 knockout. Such combination of 
genetic defects induces a fast growth of multiple tumor types. BALBp53neu 
female mice develop salivary gland carcinomas at about 13-15 weeks of age 
and mammary tumors at about 19-20 weeks. Therefore the growth of salivary 
tumors precedes the complete development of mammary carcinogenesis. At 
sacrifice, about 30% of female mice are affected by both types of tumors. 
BALBp53neu male mice are prone to develop salivary gland carcinomas and 
pelvic rhabdomyosarcoma at about 13-15 weeks of age. Since these two 
different tumors show latency time and growth rate similar, lethality can result 
from either type of neoplasms (Croci et al., 2004). 
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TRIPLEX VACCINE 
Cancer immunopreventive studies on rat HER-2/neu transgenic mice have 
produced a good number of approaches able to delay and/or reduce tumor onset 
up to a complete protection from tumor carcinogenesis driven by HER-2/neu 
oncoantigen (Lollini et al., 2006a). 
One of the most effective vaccines was set up in the BALBneuT model in the 
Laboratory of “Immunology and Biology of Metastasis” and was based on 
allogeneic neu-expressing mammary cancer cells combined with IL-12. 
Vaccine cells derived from a mammary carcinoma of a FVBneuN #202 (H-2q) 
mouse, transgenic for the rat protooncogene c-neu. Such vaccine, referred to as 
Triplex vaccine, expresses the p185neu oncoantigen and MHC molecules of the 
H-2q haplotype (allogeneic for H-2d BALBneuT mice). The third component of 
Triplex vaccine is IL-12. At first recombinant IL-12 was used and then vaccine 
cells were engineered with the genes coding for murine IL-12 (Nanni et al., 
2001; De Giovanni et al., 2004).  
The vaccination with IL-12 engineered allogeneic neu+ mammary carcinoma 
cells started at 6 weeks of age and was repeated lifelong according to a 
schedule named Chronic. This protocol consisted of 4-week cycles: in the first 
two weeks mice received two intraperitoneal (i.p.) vaccine injections per week, 
then mice had two weeks of rest. Vaccine cells were pretreated with mitomycin 
C to block the proliferation and then 2x106 cells in Phosphate Buffer Solution 
(PBS) were injected into each mouse (De Giovanni et al., 2004). The Triplex 
vaccine produced an almost complete protection from neu-driven mammary 
carcinogenesis (Nanni et al., 2001; De Giovanni et al., 2004).  
The main actors of the immune response elicited by the Triplex vaccine were 
interferon gamma (IFN-γ) and anti-p185neu antibodies. IFN-γ, produced by T 
helper 1 (Th1) lymphocytes and cytotoxic T lymphocytes (CTL), through IL-12 
induction, promotes the isotypic switch to Th1-type immunoglobulins G (IgG). 
Moreover IFN-γ causes block of cell proliferation and apoptotic cell death. The 
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killing of p185neu+ mammary carcinoma cells is mediated by classical immune 
mechanisms as well as by downmodulating the p185neu receptor. Moreover 
IFN-γ can induce production of antiangiogenic factors. Anti-p185neu antibodies 
(also referred to as anti-neu antibodies), specifically IgG2a and IgG2b murine 
subclasses, showed antitumor activities mediated both by immune mechanisms, 
such as ADCC, and by induction of p185neu recycling and inhibition of receptor 
dimerization (Nanni et al., 2001; De Giovanni et al., 2004). The importance of 
IFN-γ and anti-neu antibodies was confirmed by studies in BALBneuT mice 
lacking antibodies or IFN-γ production. In these mice Triplex vaccine loss the 
ability to prevent mammary carcinoma onset (Nanni et al., 2004).  
The Triplex vaccine was also studied in BALBp53neu mice, which are a 
more aggressive model, towards different tumor types (salivary and mammary 
in females, salivary and rhabdomyosarcoma in males). At one year of age the 
life-long administration of Triplex vaccine can prevent tumors in more than 
60% of females and 40% of males mice (Croci et al., 2004). 
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TRIPLEX VACCINE: 
FROM PRECLINIC TO CLINIC 
 
Previous studies clearly demonstrated the potency of Triplex cell vaccine as 
cancer immunopreventive approach. A future human application of cancer 
immunoprevention, and specifically of Triplex vaccine, will require specific 
studies aimed at the definition, in preclinical models, of the optimal conditions 
for a successful translation. The development of some of these preclinical 
aspects was the overall aim of the work presented in this thesis and was focused 
on three main directions:  
1) The success of Triplex cell vaccine in BALBneuT female mice was 
obtained through a cell vaccine administered lifetime with a 4-week schedule. 
The attempt to obtain equally effective protocols but with shorter vaccination 
periods or with less vaccine administrations should be pursued. This issue is 
relevant in a translational perspective, because the number of vaccinations is an 
important element in determining human acceptance and compliance. Then a 
new protocol was predicted by a mathematical simulator of immune system and 
evaluated in BALBneuT mice. 
2) Early human trials will necessarily be performed in advanced cancer 
patients in a therapeutic, rather than preventive, set-up. Therefore the 
therapeutic activity of the Triplex vaccine was investigated against 
experimental lung metastases in BALBneuT mice.  
3) DNA vaccines could be of easier clinical use in comparison with cellular 
vaccines. A second generation of Triplex vaccine based on DNA plasmids was 
evaluated in BALBp53neu female mice and compared with the preventive 
ability of cellular Triplex vaccine. 
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SECTION 1
 26 
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OPTIMIZATION OF THE TRIPLEX VACCINE 
SCHEDULE 
 
INTRODUCTION 
 
Triplex vaccine schedule 
The Triplex cell vaccine was able to prevent mammary carcinogenesis in 
HER-2/neu transgenic mice. BALBneuT mice were treated according to a very 
intensive 4-week cycle schedule. The treatment started at 6 weeks of age. Each 
vaccination cycle consisted of two injections per week for the first two weeks, 
followed by two weeks of rest (Nanni et al., 2001; De Giovanni et al., 2004). 
This schedule gave excellent results, but it consisted of a huge number of 
injections over the entire lifetime, feature that should be hardly translatable to 
humans. Looking for simpler vaccination protocols, shorter schedules have 
already been tested in BALBneuT model (Figure II). These protocols were 
based on three vaccination cycles starting at different stages of mammary 
carcinogenesis: at 6 weeks of age, corresponding to mice with atypical 
hyperplasia (“Early”), 10 weeks of age corresponding to in situ carcinoma 
(“Late”) and 16 weeks of age corresponding to incipient invasive carcinoma 
(“Very Late”). The results of the previous vaccinations were compared with 
lifetime vaccination (referred to as “Chronic”). 
BALBneuT female mice in the Early group showed the highest delay of 
tumor onset (median latency of tumors: 55 weeks of age) although all mice 
were positive for mammary tumors at 63 weeks of age. The Late schedule had a 
shorter median latency of tumors (about 40 weeks) even if the tumor-free 
survival curve was still significantly different from untreated mice one (median 
latency of tumors corresponding to about 20 weeks). Finally the tumor-free 
survival curve of the Very Late group was not significantly different from that 
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of untreated mice. Thus, a progressive loss of vaccine efficacy directly related 
to the advancement of tumor progression has been shown by these in vivo 
studies. The administration of the Triplex vaccine had necessarily to start when 
only atypical hyperplasia was present in order to give a complete prevention of 
mammary carcinogenesis (Nanni et al., 2007). 
Early protocol was simple and effective, but it only produced a delay of 
tumor onset: three vaccination cycles were not sufficient to keep mice tumor-
free at one year of age (De Giovanni et al., 2004; Nanni et al., 2007). 
 
 
Figure II. Tumor-free survival curves of BALBneuT female mice (6-7 mice for each group) 
subjected to various vaccination protocols with Triplex vaccine (Nanni et al., 2007). 
 
Two main indications were inferred to design new schedules for the Triplex 
vaccine: the treatment should not start after the 6th week of mouse age and only 
12 administrations, i.e. three vaccination cycles, concentrated in the first three 
months of treatment are not sufficient to maintain mice tumor-free up to 1 year 
of age. The definition of these conditions could contribute to the improvement 
of the vaccination protocol for the Triplex vaccine and in silico tools could help 
to design a new schedule in order to optimize Triplex vaccine treatment. 
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Tumor immunology modeling 
Biological sciences rely on modeling systems since models are fundamental 
to conceptualize, understand, test and predict phenomena. The modeling 
systems include both in vivo and in vitro models, such as genetically engineered 
mice or tumor cell lines respectively. Another class of models is defined by in 
silico approaches. In this context the term in silico means simulations of 
chemico-biological processes performed by computational and mathematical 
strategies. In silico modeling is a useful tool for several disciplines since in 
silico experiments can be performed in a fast and relatively cost-efficient way, 
compared to most wet-lab studies, thanks to the possibility to tune multiple 
parameters reproducibly and over a wide range (Deisboeck et al., 2009).  
The study of immune mechanisms has been producing new knowledge for 
the design or the improvement of vaccines (Kaufmann, 2007). Immunomics is a 
new discipline arising from the cooperation of different fields, including 
informatics, genomics, proteomics, clinical medicine and obviously 
immunology. Immunomics could offer a great contribution to vaccinology by 
the development of algorithms for the design and discovery of new vaccines or 
the improvement of pre-existing vaccines. Among immunomics research 
products, in silico techniques have been developed to identify suitable vaccine 
candidates (T cell and B cell epitope prediction, reverse vaccinology), to 
discover allergen and adjuvant molecules and to enhance the efficiency of 
protein expression (codon optimization) (Davies and Flower, 2007). 
The evolution of mathematical immunology led to the design of models able 
to explain general immunologic phenomena using basic molecular features and 
some of these models tried to describe the full immune system. One of the first 
models of this class was the IMMSIM model developed by Seiden and Celada 
(Louzoun, 2007; Forrest and Beauchemin, 2007). IMMSIM belongs to the 
category of agent based modeling, an approach that describes the interactions of 
autonomous entities (cells, agents). An agent can represent a cluster of cells, a 
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single cell, a protein or a gene. Agents interact with their environment and the 
other agents according to a set of literature-based rules. Each agent can assume 
different states as consequence of its interactions. The environment is 
represented by the simulation space and contains non cellular parameters 
relevant for the experimental question being addressed, for example 
concentrations of diffusible factors, such as chemokines or cytokines, or 
nondiffusible factors, such as the extracellular matrix. The simulation space in 
which the agents move can be given closed, open or periodic boundaries 
(Thorne et al., 2007).  
 
SimTriplex model 
The modeling of the immune system can be combined with the simulation of 
cancer growth, so that the ability of cancer vaccines to enhance an immune 
response against tumors can be tested in in silico models. These models are 
defined as immune system-tumor competition models (Lollini et al., 2006c). 
SimTriplex, described by Pappalardo and colleagues (Pappalardo et al., 
2005) is an immune system-vaccine tumor competition model developed on 
Celada-Seiden IMMSIM model. It reproduces at the cellular level the behavior 
of immune cells of Triplex vaccinated as well as untreated BALBneuT mice. 
This model belongs to the agent based modeling family, thus including a 
variety of cellular and molecular entities. Cell entities comprise B lymphocytes, 
T helper and cytotoxic T lymphocytes. Moreover other agents are represented, 
such as macrophages, dendritic cells and plasma cells. Each cell entity of 
SimTriplex model has four attributes: position, specificity, state and age.  
Position refers to the lattice-cell in which entities are located. This parameter 
is relevant since the interactions are possible only between entities co-located in 
the same lattice cell.  
Specificity refers to the set of receptor molecules which characterize each 
entity defining its ability to bind target molecules (co-receptors, peptides, 
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epitopes). A clonotypic set of cell agents is characterized by the receptor which 
is represented by a bit-string of length l; hence the potential repertoire scales as 
2l. The binding is described as a matching between binary strings with fixed 
directional reading frame. The Hamming distance measures the match between 
bit-strings of length l: two bits match if they are complementary. Thus, 0 
matches 1 and vice versa. If the number of matches is above the binding 
threshold, which is a parameter of the simulation, then the agents interact. The 
binding is maximal when all corresponding bits are complementary and so the 
Hamming distance is equal to the bit string length (Forrest and Beauchemin, 
2007).  
The state defines the internal state of each cell entity and the number of states 
is different among several entity types. Each cell can be in a different internal 
state and all cells are tracked individually throughout the course of an 
experimental run.  
Finally the age is related to the entity age structure. To keep track of the age 
of cellular entities, the number of time-steps, since the cell birth, is counted. To 
simulate memory cells, the half-life of T helper, cytotoxic T and B cells is 
increased after successful interaction with target antigens. The death probability 
reaches 1 when the age gets to twice the half-life. 
Molecular entities included in the simulator are antigens, antibodies, 
cytokines (IL-2, IFN-γ), MHC I/II and danger signals. Molecular entities do not 
have internal states and thus do not need to be modelled individually. They are 
defined for their position and lifetime. Diffusion on the lattice is described by 
appropriate change of their concentrations. 
All these entities are governed by a set of rules. These rules, about 15, 
resume the main activities of the immune system: phagocytosis, immune 
activation, opsonization, infection and cytotoxicity. 
The model reproduces a portion of mammary tissue (1 mm3 of the mouse) 
that is represented as two-dimensional triangular lattice (six neighbour sites), 
with periodic boundary conditions in both directions. Cells and molecules are 
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free to move across the lattice sites. At each time step, representing 8 hours of 
real time, cells and molecules residing on the same lattice are able to interact 
with each other. 
The tumor growth and the Triplex vaccine activity are reproduced by the 
cancer cells agents, which encode their tumor-associated antigens, and the 
vaccine cells agents, which include tumor-associated antigens, IL-12 and 
allogeneic MHC I, respectively. These two cell entities interact with immune 
entities and between them. The growth of cancer cells is reproduced including 
three new cancer cells in the lattice at every time step. Once inserted in the 
system, cancer cells duplicate, and very rarely die by apoptosis. The cancer cell 
duplication is included as a probabilistic event at each cancer cell once per 
cycle. The cancer cell population grows following an exponential law with 
parameters chosen to fit qualitatively the tumor growth observed in the real 
mice. The model assumes that a solid tumor is formed when the number of 
cancer cells in the lattice is over 105. Vaccine cells are modified tumor cells, 
which can not duplicate and have a half life of 1 day (Pappalardo et al., 2005). 
The model has been tuned and validated against existing in vivo experiments 
as described by Motta and colleagues (Motta et al., 2005).  
 
AIM 
This part of the study had two goals: 1) to identify a candidate optimal 
vaccination schedule for the Triplex cell vaccine through the SimTriplex 
simulator and a genetic algorithm; 2) to test its efficacy in vivo in BALBneuT 
mice in comparison with Chronic and other schedules. 
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RESULTS 
 
In silico research of optimizing vaccination protocols for Triplex 
SimTriplex simulator can simulate in about 30 seconds an in vivo experiment 
lasting one year. Taking into account that the actual duration of one in vivo 
experiment is 400 days and that vaccinations are usually administered twice 
weekly, the number of days available for vaccine administration is about 100. 
So the possible different schedules are 1030. Although an in silico experiment is 
faster than a real one, the number of possible schedules is too high (about 1030) 
and the time required to test them exceeds any possible present or future 
computational capacity (Nicoletti et al., 2009). 
Thus, looking for an optimized vaccination schedule for Triplex cell vaccine, 
the SimTriplex simulator was used in combination with a specific genetic 
algorithm, in which a vaccine schedule is represented as a binary vector in 
which each position is a time step of the simulator. If a vaccine was 
administered at that time step, the vector element is set 1, otherwise is 0. The 
thus constructed binary vector represents a vaccine schedule. The genetic 
algorithm tried to find the best vector which minimizes the objective functions. 
In order to set up the objective functions three fundamental and competing 
requirements were considered: 1) any schedule had to be an effective one, i.e. 
the mouse survival time must reach 400 days; 2) the best schedule had to 
provide mice survival with the minimal number of vaccine injections; 3) the 
number of cancer cells had to be unable both to induce an anergic state of T 
lymphocytes and to form carcinoma in situ. Moreover the schedule had to be 
optimal not only for a mouse but for a set of mice. Finally, other practical 
constraints applied to the genetic algorithm were that the vaccinations had to be 
administered only in working days, with a maximum of two injections per week, 
each followed by two/three days of rest (Lollini et al., 2006b; Lollini et al., 2008). 
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Through in silico tools a candidate optimal protocol named Genetic was 
identified. It was characterized by 32 injections, i.e. almost 50% less than the 
Chronic protocol, and a predicted tumor-free survival at 63 weeks of age of 
81% (Figure 1). The Genetic protocol was then tested in vivo in order to 
evaluate the efficacy of the schedule in BALBneuT mice and validate the 
simulator. 
 
In vivo experimental design 
The preventive ability of the Triplex vaccine consisting of allogeneic IL-12 
engineered neu+ mammary carcinoma cells (Neu/H-2q/IL-12) administered 
according to the Genetic schedule was evaluated in BALBneuT female mice. 
The experimental design consisted of five experimental groups of mice: 
Untreated, Chronic-63, Early, Genetic and Heuristic (Figure 1). 
Untreated mice represented the “negative control” group. Previous 
experiments indicated that all BALBneuT female mice, if untreated, develop 
mammary tumors around the 20th week of age. Thus this group showed the 
baseline level of mammary carcinogenesis. 
The “positive control group” included mice treated with Triplex cell vaccine 
according to the Chronic protocol. Previous experiments showed that the 
tumor-free survival was about 85-100% at more than one year of age. The 
treatment started at 6 weeks of age and was interrupted at the 63rd week of age. 
Mice received 60 injections of Triplex vaccine. This schedule was therefore 
referred to as Chronic-63. 
A third group of mice was treated according to the Early protocol. As 
reported above, this treatment induced a strong delay in tumor onset but shortly 
after a year of age all mice were positive for tumor. The previously obtained 
tumor-free survival curve was intermediate between the Untreated and Chronic 
schedule curves and significantly different from both of them. The Early 
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protocol started at the 6th week of age. The last administrations were performed 
at 15 weeks of age and the schedule consisted of a total of 12 injections. 
The fourth group was treated according to the Genetic protocol. The 
vaccination started at the 6th week and ended at the 55th week. This schedule 
consisted of 32 administrations irregularly distributed over the time with a 
higher density at earlier time points. So this schedule was different from Chronic-
63 in two aspects, i.e. number of vaccinations and intervals. The predicted tumor-
free survival was 81% at 63 weeks of age. 
In the last group mice were treated according to a schedule named Heuristic. 
This treatment consisted of almost the same number of vaccinations, 30 injections, 
as the Genetic schedule, but regularly spaced (from the 6th to the 63rd week of age). 
SimTriplex simulator predicted a 65% tumor-free survival for this protocol at 63 
weeks of age. 
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Figure 1. Tumor-free survival curves of BALBneuT female mice vaccinated according to 
various schedules: Chronic-63 (n=11), Early (n=10), Heuristic (n=13), Genetic (n=12). 
Untreated mice (dotted line, n=7). The vaccination schedules are shown at the top of the figure. 
Each bar represents an injection. Significance of differences with Mantel-Haenszel test: Genetic 
vs Chronic-63, p<0.01; Early/Heuristic vs Chronic-63, p<0.001. Survival curves of Early, 
Genetic and Heuristic groups were not statistically different from one another. 
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In vivo experiments: tumor-free survival  
All treatments started at the 6th week of age. Mice were thereafter examined 
weekly for the presence of palpable mammary carcinomas.  
The tumor-free survival curve of the Untreated BALBneuT group showed 
that all mice developed the first tumor within the 21st week of age (Figure 1). 
Thus the baseline level of mammary carcinogenesis was overlapping historical 
data. The follow-up of the experiment at more than one year of age showed that 
the kinetics of tumor onset were significantly different for all four treated mice 
groups compared to the Untreated group. Therefore a protective ability of 
Triplex cell vaccine was obtained with all the vaccination schedules. However, 
only the Chronic-63 protocol vaccination gave a complete protection from 
mammary carcinogenesis (Figure 1). 
The tumor-free survival curve of mice treated with Genetic, Early and 
Heuristic protocols were significantly different compared to the Chronic-63 one 
but they did not significantly differ among them (Figure 1).  
In the Early protocol a progressive fall in tumor-free survival curve was 
observed, as expected (Figure 1).  
At 63 weeks of age Genetic group had 33% tumor-free mice, a value lower 
than that expected by the simulator prediction (81%). Tumor-free mice in the 
Heuristic protocol was 31%, lower than that predicted by the simulator (65%) 
(Figure 2). 
Therefore, the simulator correctly ranked the preventive efficacy (Genetic 
better than Heuristic), but further improvements should be made to obtain a 
more precise prevision in terms of tumor-free survival curves. 
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Figure 2. Comparison between tumor-free survival curves obtained by in vivo (solid lines) and 
in silico (dotted lines) experiments. Genetic schedule (red), Heuristic schedule (pink). 
 
Triplex efficacy and aging 
As reported above, the Chronic-63 schedule was interrupted at 63 weeks of 
age, i.e. after 60 administrations. At that time all mice were free from tumors. 
Prolonging the follow-up after the 63rd week of age (Figure 3), it was observed 
a fast fall in the percentage of tumor-free mice with 100% of mice positive for 
tumors within about 100 weeks. This result proved that prevention requires 
periodic boosts even after a year of repeated vaccinations. With life-long 
Chronic vaccination, tumor onset was only observed after 100 weeks of age 
(data not shown). 
We compared the fall of tumor-survival curve of Early and Chronic-63 
schedules. In both groups mice were all free from tumors at the end of 
vaccination, but kinetics of tumor onset thereafter were different. The gap 
between the last vaccination and the median latency of mammary tumor was 37 
weeks for Early group and only 15 weeks for the Chronic-63 group. The Early 
protocol induced a more lasting anti-tumor response in young mice than the 
Chronic-63 protocol in old mice (Figure 3).  
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Figure 3. Tumor-free survival curves of BALBneuT mice vaccinated according to Early (black 
circle) or Chronic-63 (blue square) schedules; Untreated mice (dotted line). The grey thin lines 
indicates the last vaccination cycle for Early (left) and Chronic-63 schedules (right). The gap 
between the last vaccination and the median latency of mammary tumors was 37 weeks for 
Early group and only 15 weeks for the Chronic-63 group. 
 
In vivo experiments: tumor progression 
Even though tumor-free survival curves of Genetic, Heuristic and Early 
protocols were not significantly different among them, some differences in 
tumor progression was observed when tumor multiplicity (i.e. the mean number 
of tumors per mouse) was examined. Genetic protocol showed a lower tumor 
multiplicity than Heuristic, with a significant difference between 35 and 49 
weeks of age. The tumor progression of the Early group was intermediate 
between Heuristic and Genetic ones, although this curve was not significantly 
different from the curves of the two other protocols (Figure 4).  
Genetic and Chronic groups showed similar kinetics of tumor progression up 
to 50 weeks of age, whereas after this time the Genetic group showed a rise in 
tumor multiplicity (Figure 4). 
Genetic protocol was more effective in controlling the development of 
multiple tumors compared to Early and Heuristic schedules. On the whole the 
total number of tumors observed in Genetic group was lower than the number 
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of tumors of the two other protocols at 63 weeks of age. Thus, considering the 
cumulative number of tumors at this age, the Genetic schedule prevented 71% 
of tumors while Early and Heuristic schedules 41% and 48% respectively, in 
comparison to untreated controls.  
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Figure 4. Tumor multiplicity per mouse (mean; bars, SE). Chronic-63 (n=11), Early (n=10), 
Heuristic (n=13), Genetic (n=12); Untreated mice (n=7). Statistical significance: Genetic vs 
Heuristic p<0.05 between 35 and 49 weeks of age; Genetic vs Early not significant; Heuristic vs 
Early not significant; Genetic vs Chronic-63 p<0.05 at least between 54 and 63 weeks (Student 
t test). 
 
In vivo experiments: anti-vaccine antibodies 
Previously published data proved that anti-vaccine antibodies are essential 
for cancer immunoprevention induced by Triplex cell vaccine. To study such 
effector mechanism in relation to the efficacy of different vaccination 
schedules, mice were bled every four weeks, starting from 9 weeks of age, to 
quantify the serum levels of anti-vaccine antibodies (Figure 5). The mean value 
of anti-vaccine antibodies for each group was compared at fixed time points, 
i.e. after 4, 8, 12,…weeks of vaccination, although each protocol consisted of a 
different number of injections during the same period. As an example in the 
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first eight weeks of vaccination, Chronic-63 and Early consisted of 8 
administrations, Heuristic 4, Genetic 5. 
All treated mice produced anti-vaccine antibodies but differed in antibody 
kinetics and levels. Chronic and Early protocols (which share the same 
schedule and only differ after the stop of vaccinations for Early group at 15 
weeks of age) showed a very fast increase in anti-vaccine antibody levels, 
which reached the top at about 17 weeks of age with median fluorescence 
intensities approaching 1000 arbitrary units. After the stop of vaccination, 
however the antibody curve of the Early group began to fall. Genetic schedules 
caused a slightly slower rise in antibody level, reaching a maximal value 
similar to those of Chronic and Early groups but only after 21 weeks of age. 
Heuristic group showed a very slow rise in antibody level.  
A comparison between these data and tumor-free survival curves suggested 
that vaccine-induced antibodies must reach quickly a safety threshold 
(identified above 700 arbitrary units of median fluorescence intensity) in order 
to prevent mammary carcinoma. Then, this level should be kept above the 
threshold for the entire lifespan of the mouse. A slow increase of antibody titer 
or a decrease of this level correlate with tumor onset at 1 year of age, as proved 
by Heuristic and Early protocols that were less protective than other schedules. 
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Figure 5. Kinetics of anti-vaccine antibodies (mean with n= 2-13; bars, SE). Sera of mice 
(diluted 1:65) were investigated for the presence of antibodies through binding to Neu/H-2q 
cells and cytofuorometric analysis. 
 
 
The results reported above will be included in a manuscript in 
preparation. 
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DISCUSSION 
Triplex cell vaccine could prevent almost completely mammary tumor onset 
in BALBneuT female mice if administered according to a life-long protocol 
referred to as Chronic. However, no previous studies investigated if all the 
administrations of the Chronic schedule are necessary. The present research 
work aimed at looking for an optimal schedule for the Triplex cell vaccine, i.e. 
a schedule with a reduced number of treatments but maintained efficacy.  
The in silico model SimTriplex driven by a genetic algorithm, led to the 
design of a vaccination protocol, referred to as Genetic, that was tested in vivo 
in BALBneuT female mice. It consisted of only 32 administrations, against 60 
injections of the Chronic-63 protocol (i.e. a Chronic schedule stopped at 63 
weeks of age). In silico runs predicted a high protective ability of the Genetic 
protocol with 81% of tumor-free mice at the end of experiment. The in vivo 
testing included five experimental groups of mice: Untreated, Chronic-63, 
Early, Genetic and Heuristic. The latter schedule consisted of almost the same 
number of vaccinations, 30 injections, as the Genetic schedule, but regularly 
distributed. SimTriplex simulator predicted for this protocol 65% tumor-free mice 
at 63 weeks of age. 
The tumor-free survival curves of the Genetic and Heuristic groups produced 
by in vivo experiments only partially confirmed the prediction of the simulator, 
giving evidence of a protective ability lower than expected. 
Though the first version of SimTriplex did not include the concept of 
multiple mammary areas, taking into account the overall rate of mammary 
tumors developed in each mouse within the 63rd week of age, the Genetic 
schedule was able to prevent the 71% of tumors and the Heuristic protocol 48% 
in comparison to the untreated mice. These data were closer to the simulator 
prediction than tumor-free survival curves. 
As reported (Nanni et al., 2004), anti-vaccine antibodies are a predictive 
marker of the protection level induced by the Triplex vaccine. The comparison 
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of antibody kinetics among groups showed a slower increase of antibodies for 
the Heuristic group. The slow rise of antibody level was probably caused by the 
small number of injections (only 2) in the first month of treatment compared 
with 4 administrations of the Chronic-63, Early and Genetic protocols. 
As a consequence the first month of treatment, and in particular the first two 
weeks, seem to be relevant to ensure a fast increase of anti-vaccine antibodies. 
In this way an antibody level above the 700 arbitrary units of median 
fluorescence, identified as safety threshold, might be reached within the third 
month of the treatment. 
The anti-vaccine antibody curve of the Early treatment suggested another 
issue; the absence of boosts after the first three months of vaccination was 
followed by a progressive decrease of antibodies that paralleled the fall in the 
protective ability. Consequently an effective immunopreventive schedule for 
the Triplex vaccine should maintain a level of anti-vaccine antibodies above the 
threshold for the entire life-span of the mouse in order to ensure a high 
protection. 
The anti-vaccine antibody curve of the Genetic group showed a more rapid 
increase than the Heuristic one during the first weeks of treatment. On the other 
hand, the anti-vaccine antibody level of the Genetic group reached after a 
month of treatment, was slightly lower than the antibody levels of Chronic-63 
and Early groups, even if in the first month all the three schedules consisted of 
4 injections. A reason could be that in Genetic schedule the 4th administration 
was performed too late (on 24th day of treatment) to give a contribution to the 
increase of antibody level in the first month (first point of the curve). Then the 
mean antibody level of the group remained over the threshold until about 50 
weeks of age, much longer than the Early schedule. Subsequently it started to 
decrease and consequently the tumor-free survival, too. These two peculiarities 
of the Genetic curve may justify its lower efficacy compared with the Chronic-
63 protocol. 
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The tumor-free survival curve produced by mice treated with the Chronic-63 
protocol showed that the absence of boosts after 63 weeks of age caused a fast 
tumor onset since after only 15 weeks 50% of treated mice had already 
developed mammary carcinoma. Therefore multiple vaccination cycles, i.e. 60 
administrations, were not sufficient to ensure a prolonged immune protection 
against tumor after the end of vaccination: further boosts are required. 
Dominguez and colleagues (Dominguez and Lustgarten, 2008) showed that 
tolerant mice cannot develop memory responses against self tumor antigens. 
This consideration could justify the rapid increase of tumor onset in 
BALBneuT mice after stopping the Chronic-63 treatment.  
The comparison of tumor-free survival curves of Early and Chronic-63 groups 
shows that younger mice maintained an anti-tumor immune response for longer 
time after vaccine stop than elder mice. As reported by Dominguez and 
colleagues (Dominguez and Lustgarten, 2008), elder mice have a higher 
number of Treg cells than younger ones. However they observed that the 
depletion of Treg cells in combination with vaccination induced an effective 
anti-tumor response and developed immune memory only in younger mice. 
They justify the low efficacy of this combined treatments in elder mice 
considering that these mice accumulate some defects that, influencing the 
immune system, reduce the activation of immune response. For this reason the 
depletion of Treg cells alone might not be sufficient for the complete 
restoration of immune responses in old tolerant hosts. Therefore Treg cells and 
other factors could contribute to a more rapid decrease of the protective 
response in the Chronic group than in the Early group.  
In vivo validation of the SimTriplex simulator by testing the vaccination 
schedules in BALBneuT mice did not fully confirm the expected protective 
efficacy of the Genetic and Heuristic schedules in terms of tumor-free survival 
time. Quantifying the protective ability as percentage of prevented tumors 
compared to untreated mice, in vivo and in silico results are closer. 
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As reported in other studies (Croci et al., 2004; Cipriani et al., 2008) the 
level of anti-vaccine antibodies at specific time points can predict the ability of 
a vaccine to prevent tumor onset. This indication was confirmed by the analysis 
of anti-vaccine antibodies kinetics of the above described in vivo experiments. 
Reaching the safety threshold as soon as possible and maintenance of the 
antibody level above this threshold seem to be related to vaccine preventive 
efficacy. 
Data produced by in vivo validation of the simulator could be used for a 
second tuning of SimTriplex model. Moreover in order to improve the 
simulations to better reflect these experimental results, a particular attention 
should be given to the simulation of precocious vaccine-induced immune 
responses and to the different immune response in younger and elder mice. 
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SECTION 2 
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ANTIMETASTATIC ACTIVITY OF THE TRIPLEX 
VACCINE 
 
INTRODUCTION 
 
Cancer vaccines: Immunoprevention versus Immunotherapy 
Cancer vaccines represent an immunologic approach which can be applied 
both to immunoprevention and immunotherapy of tumors. The aim of cancer 
immunotherapy is the eradication of existing tumors. Cancer 
immunoprevention implements cancer vaccines before tumor onset to induce an 
immune response that protects the host from carcinogenesis and tumor 
progression.  
The targets of immunotherapeutic cancer vaccines are established malignant 
tumors. A large neoplastic mass is generally able to grow rapidly and to 
activate a great number of immunosuppressive strategies, thus it is more 
resistant to an immunologic attack than a small pre-neoplastic lesion. The 
activity of several genes is compromised after early genetic alterations and this 
instability increases with the tumor progression. The selective pressure exerted 
by the immune system can lead to the selection of tumor clones. Thus a weak 
immune response could select tumor variants that are less antigenic and less 
sensitive to immune attack (Lollini et al., 2006a). Concerning immune 
mechanisms, it was shown that the long-term efficacy of vaccines used to 
prevent carcinogenesis is mediated more by antibodies than by CTL, that are 
the main actors of cancer immunotherapy (Nanni et al., 2007). Consequently a 
vaccine that is effective in a preventive setting could lose its efficacy in a 
therapeutic context since the target of the treatment, together with immune 
effectors required, are different. 
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Immunopreventive vaccines and clinical trials 
The essential distinction between prevention and cure, however, is less 
striking in the transition from experimental models to clinical practice, as a 
hypothetical first human implementation of immunopreventive vaccines, phase 
I and phase II studies, should be performed in cancer patients, i.e. in a 
therapeutic context rather than preventive one. The use of cancer vaccines with 
a therapeutic aim in human patients has achieved poor results so far, partial 
responses are rare and complete responses extremely rare (Lollini et al., 2006a; 
Finn, 2008; Rice et al., 2008).  
Poor therapeutic activity of these vaccines in preclinical studies announced 
many negative results subsequently obtained in clinical trials. Thus mouse 
models can help to investigate if an immunopreventive vaccine could be 
effective also against a pre-existing tumor mass. If a vaccine looks effective, 
the study should be focused on the immune mechanisms activated against 
tumor mass and on the comparison with immunopreventive ones. 
 
Triplex vaccine and in vivo therapy  
The Triplex vaccine loses progressively its efficacy with the advancement of 
tumor progression in BALBneuT mice (Nanni et al., 2007). It was observed 
that this vaccine had little or no efficacy at all against incipient mammary 
carcinomas. 
A key step of malignant tumor progression after local growth is metastatic 
dissemination, which represents a restriction point together with early tumor 
onset. 
 
AIM 
This study was developed to evaluate the therapeutic power of the Triplex 
cell vaccine against the development of experimental lung metastases. 
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RESULTS 
 
Therapy of lung metastases with Triplex cell vaccine in tolerant 
mice 
TUBO mammary carcinoma neu+ cells (referred to as Neu/H-2d) were used 
in this study to induce neu+ experimental metastases (Figure 6A) in syngeneic 
BALBneuT mice. At day 7 after TUBO injection, mice entered the vaccination 
protocol with Triplex cell vaccine (Neu/H-2q/IL-12). Control groups included 
untreated mice (None) and mice treated with single “components” of the 
Triplex vaccine: recombinant IL-12, mammary carcinoma neu+ syngeneic cells 
(Neu/H-2d) or allogeneic mammary carcinoma cells (Neu/H-2q).  
The great number of injected cells (2.5x104 cells) causing a high metastatic 
burden and the choice of starting the vaccination at day 7 when cells had 
already established metastatic deposits (Figure 6A) contributed to obtain 
stringent and realistic preclinical conditions. 
As shown in Table 1, the Triplex cell vaccine produced more than 87% 
reduction of lung nodules in BALBneuT mice compared to untreated mice. The 
study of semiserial sections showed that the number and the dimensions of lung 
metastases after 14, 21, and 28 days were lower in vaccinated mice than in 
untreated mice; moreover, the structure of metastatic lesions was frequently 
cribriform and less compact than in controls (Figure 6B). All the three stimuli 
of Triplex vaccine were essential to obtain this good result, since the three other 
“incomplete” vaccines did not show significant curative ability (Table 1). 
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Figure 6. Metastatic development in untreated and vaccinated BALBneuT mice. A, mammary 
carcinoma metastases developing in the lungs of BALBneuT mice seven days after the i.v. 
injection of TUBO cells (left panel, hematoxylin and eosin, 400×, right panel, HER-2/neu 
immunohistochemistry, 400×). B, HER-2/neu-stained metastases in the lungs of untreated and 
vaccinated mice (25×); vaccination started 7 days after metastasis induction, mice were 
sacrificed 21 days later. 
Vaccinated Untreated 
A 
B 
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Table 1. Therapeutic vaccination of mice bearing lung micrometastases. 
Lung nodules 
Mice Start
1
 of 
vaccination Group Vaccination Incidence Median Range 
BALBneuT Day 7 (a) None 9/9   (100%) >200 134->200 
 
 (b) IL-12 5/5   (100%) 86 42->200 
 
 (c) Neu/H-2d 5/5   (100%) 117 89->200 
 
 (d) Neu/H-2q    4/4   (100%) 124 59->200 
 
 (e) Neu/H-2
q/IL-12 
(Triplex) 12/12 (100%) 26
¶
  1-165 
       
 
Day 1 (f) None  10/10 (100%) >200 80->200 
 
 (g) IL-12 5/5   (100%) 60$  23-153 
 
 (h) Neu/H-2q 5/5   (100%) 81$  76->200 
 
 (i) Neu/H-2
q/IL-12 
(Triplex) 9/10   (90%) 3
§ 
 0-27 
       
BALB/c Day 7 (l) None  10/10 (100%) >200 47->200 
 
 (m) Neu/H-2d 5/5    (100%) 79† 27-97 
 
 (n) Neu/H-2q 4/5      (80%) 11† 0-21 
 
 (o) Neu/H-2
q/IL-12 
(Triplex)    1/11      (9%) 0
‡
 
 
0-4 
       
 
Day 1 (r) None 18/18  (100%) >200 95->200 
  
(s) Neu/H-2q 0/5        (0%) 0* 0-0 
    
(t) Neu/H-2
q/IL-12 
(Triplex) 0/15      (0%) 0* 0-0 
1Days after the i.v. challenge with TUBO cells.   
Significance (Wilcoxon rank sum test): 
¶ vs a, b, c and d,  p<0.05 at least; $ vs f, p<0.05 at least; § vs f, g and h, p<0.01 at least; † vs l, p<0.01 at 
least; ‡ vs l, m and n, p<0.01 at least; *  vs r, p<0.001. 
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Therapy of early lung metastases 
Even if the Triplex vaccine showed a high anti-metastatic activity, all 
vaccinated mice still had sizable metastatic burdens. A possible limiting factor 
could be the advancement of the metastatic stage. Therefore the beginning of 
vaccination was anticipated at day 1 after the i.v. injection of Neu/H-2d cells. 
The Triplex cell vaccine produced a stronger antimetastatic effect, giving a 
99% reduction of the metastatic development. Under these experimental 
conditions recombinant IL-12 and Neu/H-2d cells alone gave a significant 
antimetastatic effect, but did not reach Triplex vaccine efficacy (Table 1). 
 
Therapy of lung metastases in nontolerant mice 
BALB/c mice have the same background of BALBneuT mice but are not 
tolerant for p185neu antigen, while BALBneuT mice are tolerant for p185neu 
antigen. Data reported in Table 1 show that the elimination of this limiting 
factor improves the efficacy of the Triplex cell vaccine. In fact more than 90% 
of BALB/c mice treated with Triplex vaccine from day 7 did not develop lung 
nodules. A significant antimetastatic effect was also reported for vaccinations 
with syngeneic and allogeneic neu+ mammary cancer vaccines lacking IL-12. 
The beginning of the vaccination at day 1 produced a complete protection from 
lung metastases both for the Triplex vaccine and allogeneic cell vaccine lacking 
IL-12 (Neu/H-2q). 
 
Depletion of Treg cells enhances antimetastatic efficacy 
The stronger therapeutic activity of the Triplex vaccine in nontolerant 
BALB/c mice confirmed that tolerance is a limiting factor for vaccine efficacy. 
In order to increase the Triplex cell ability in tolerant BALBneuT mice, host 
tolerance was manipulated through a transient block of regulatory T cells, since 
Treg cells contribute to the maintenance of tolerance in vivo (Ambrosino et al., 
2006). 
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BALBneuT mice bearing lung metastases received multiple i.p. injections of 
an anti-CD25 mAb named pC61 (see “Materials and Methods”). Such 
treatment enhanced significantly the efficacy of Triplex cell vaccine (Table 2): 
vaccination started at day 7 reduced metastatic lung nodules of 99% compared 
to untreated group, with an efficacy similar to that obtained in BALBneuT mice 
without Treg depletion and starting the vaccination at day 1.  
 
Table 2. Therapeutic vaccination of BALBneuT mice selectively depleted of Treg cells. 
Lung nodules Depletion Group Vaccination Start
1
 of 
vaccination  
Incidence Median Range 
None (a) None      12/12  (100%) 190 80->200 
   
    
None  (b) Neu/H-2q/IL-12  Day 7    5/5    (100%) 30 4-68 
Treg  (c) Neu/H-2q/IL-12  Day 7    4/6      (67%) 3*  0-24 
None  (d) Neu/H-2q/IL-12 Day 1   9/10    (90%) 3 0-27 
Treg  (e) Neu/H-2q/IL-12 Day 1        2/6      (33%) 0# 0-11 
1Days after the i.v. challenge with TUBO cells. 
Significance (Wilcoxon rank sum test): * vs b, p<0.05 at least; # vs d p<0.05 at least. 
 
Immune response elicited by the Triplex vaccine 
Sera of untreated and treated BALBneuT mice were collected and 
investigated for the presence of anti-vaccine antibodies, that mainly consist of 
anti-p185neu antibodies (Nanni et al., 2001). Cytofluorometric analysis of these 
samples showed a high level of antibodies that increased significantly in Treg 
depleted mice vaccinated with Triplex (Figure 7, upper panel). 
Then spleen cells of untreated and vaccinated mice were collected and 
cultured for six days with different target cells: mammary carcinoma neu 
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negative allogeneic cells (Neuneg/H-2q), mammary carcinoma neu+ syngeneic 
cells (Neu/H-2d) and mammary carcinoma neu+ allogeneic cells (Neu/H-2q). 
The ability of restimulated lymphocytes to secrete IFN-γ and IL-4 in the 
supernatants was evaluated by ELISA tests. IFN-γ was already evident in 
spontaneous splenocyte cultures of vaccinated mice (without restimulation) and 
increased significantly after restimulation with target cells. Cells expressing 
allogeneic MHC alone or p185neu alone were able to restimulate spleen cells but 
the combination of these two different stimuli produced the highest level of 
IFN-γ (Figure 7, middle panel). Finally, IL-4 production was observed both for 
unstimulated spleen cells and for cells co-cultured with neu+ cell lines (Figure 
7, lower panel).  
CTL assays against neu+ syngeneic mammary carcinoma target cells did not 
reveal any significant activity above background (data not shown).  
Immunohistochemical studies were performed in order to analyze local 
antimetastatic immune responses in the lungs of vaccinated mice. Analysis 
revealed a low reactive infiltrate at all examined time points. However a slight 
increase in the presence of CD4+ T cells at the 14th day and of macrophages and 
granulocytes at the latter time points were observed in vaccinated mice (Figure 
8, left panel), whereas no difference was found in the presence of CD8+ T and 
B220+ B cells at any time point (data not shown). Foxp3+ regulatory T cells 
were not observed in the lungs of both vaccinated and untreated mice. The 
vascularization around and inside metastases and the expression and staining 
intensity of the HER-2/neu product were similar in vaccinated and control 
mice. 
Electron microscopy showed that several macrophages in vaccinated mice 
were in close contact with tumor cells particularly at the metastasis periphery, 
where some of them showed aspects of necrosis (Figure 8, right panel). 
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Figure 7. Humoral and cellular immune 
responses induced by the Triplex cell 
vaccine (Neu/H-2q/IL-12) in BALBneuT 
mice. Upper, binding of mice sera 
(diluted 1:65) to Neu/H-2q cells as 
evaluated by cytofuorometric analysis. 
Each bar represents the mean of 5-10 
mice bled after seven vaccine 
administrations. Statistical significance: 
vaccinated mice vs untreated, p<0.005, 
Treg depleted mice vs non-depleted mice, 
p<0.05 (Student’s t test). Middle, release 
of IFN-γ by splenocytes of untreated and 
vaccinated mice. Spleen cells were 
incubated in vitro for six days alone or 
with mitomycin C-treated tumor cells 
expressing allogeneic MHC glycoproteins 
(Neuneg/H-2q), p185neu (Neu/H-2d), or 
both (Neu/H-2q). Supernatants were 
collected for cytokine ELISA assay and 
splenocytes were recovered and counted. 
Each bar represents the mean of 10 mice. 
Statistical significance: all vaccinated 
groups vs untreated controls, p<0.001 at 
least; restimulation with Neu/H-2q vs 
unstimulated or other restimulations, 
p<0.001 (Student’s t test). Lower, release 
of IL-4 by splenocytes of untreated and 
vaccinated mice, culture conditions as 
above for IFN-γ. Statistical significance: 
all vaccinated groups vs untreated 
controls, p<0.01 at least; restimulation 
with Neu/H-2q vs restimulation with 
Neu/H-2d, p<0.01 (Student’s t test). 
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Figure 8. Antimetastatic immune 
responses induced by vaccination in 
mice treated 7 days after i.v. tumoral 
cell injection. Left panel, 
immunohistochemical stainings 
performed on untreated and 
vaccinated mice showed in 
vaccinated mice an increase in the 
presence of CD4+ cells (200×) 7 days 
after vaccination and of macrophages 
and granulocytes 14 days after 
vaccination (630×). Right panel, 
electron micrograph showing a 
metastatic aggregate occupying the 
lumen of a lung capillary lined by 
endothelial cells (E) and flat 
protrusions of pneumocyte 
cytoplasms. A macrophage (M) is in 
close contact with the epithelial 
tumoral cell (T). A severely damaged 
cell with clear aspects of necrosis 
(N) is visible (2800×). 
 
CD4 
PMN 
Mϕ 
Vaccinated Untreated 
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Antimetastatic immune mechanisms 
To study immune mechanisms elicited by the Triplex vaccine, experiments 
with mice deficient in various immune responses were conducted.  
Rag2-/-/γc-/- mice lack B, T and NK populations and their products like 
antibodies and cytokines. The Triplex vaccine in these mice did not modify 
both incidence and median number of lung nodules (Table 3). 
 
To analyze the contribution of T cells, CD4+ and CD8+ T populations were 
depleted in BALBneuT mice by specific anti-CD4 and anti-CD8 antibodies (see 
“Materials and Methods”). All CD4-depleted vaccinated mice (Table 4) 
developed lung metastases. The median number of lung nodules was 
significantly increased compared to vaccinated mice without depletion 
Table 3. Therapeutic vaccination of immunodeficient mice. 
Lung nodules Immune 
deficit Group Vaccination Incidence Median Range 
None  (a) None 10/10     (100%) >200 47->200 
 (b) Neu/H-2q/IL-12 1/11          (9%) 0 0-4 
Rag2-/-; γc-/- (c) None 4/4        (100%) >200 >200->200 
 (d) Neu/H-2q/IL-12 5/5*          (100%) >200* >200->200 
µMT (e) None 11/11      (100%) 185 51->200 
 (f) Neu/H-2q/IL-12 3/7 #             (43%) 0# 0-2 
IFN-γ-/- (g) None 5/5        (100%) 185 86->200 
 
(h) Neu/H-2q/IL-12 6/6*      (100%) 22* 2-65 
Significance (Fisher’s exact test or the Wilcoxon rank sum test as appropriate): 
*vs b, p<0.01 at least; # vs b, not significant  
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confirming that T helper cells have an important role in the antimetastatic 
immune mechanisms elicited by the vaccine. Depletion of CD8+ cells did not 
significantly modify Triplex vaccine efficacy. These data are in agreement with 
the negative results of in vitro CTL assays. The third investigated population 
was NK cells, depleted by anti-asialo GM1 antiserum. The Triplex vaccine 
efficacy was not modified by NK cell depletion. Therefore NK population did 
not play a role in mediating the activity of the vaccine (Table 4). 
In vitro tests and previous data on immune effectors elicited by Triplex 
vaccine (Nanni et al., 2004) showed that a major contribution of cell-mediated 
immunity to cancer immunoprevention was through the release of cytokines, in 
particular IFN-γ and anti-vaccine antibodies production. To investigate if IFN-γ 
played a causal role in the antimetastatic efficacy, nontolerant IFN-γ deficient 
mice were vaccinated. In the absence of this cytokine a significant loss of 
efficacy of the vaccine was found, and all mice developed a sizeable metastatic 
burden compared to vaccinated nontolerant mice, thus confirming the key role 
of IFN-γ. On the contrary Triplex vaccine maintained a significant 
antimetastatic efficacy in nontolerant antibody-deficient mice (µMT) 
suggesting that the presence of anti-vaccine antibodies was not fundamental for 
therapeutic efficacy (Table 3).  
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Table 4. Therapeutic vaccination of BALBneuT mice selectively depleted of immune cell populations. 
Lung nodules Depletion Group Vaccination Start
1
 of 
vaccination  
Incidence Median Range 
None (a) None      12/12  (100%) 190 80->200 
 
      
None (b) Neu/H-2q/IL-12 Day 1   4/5      (80%) 4 0-27 
CD4 (c) Neu/H-2q/IL-12 Day 1     6/6    (100%) 39* 7-121 
CD8 (d) Neu/H-2q/IL-12 Day 1   5/5    (100%) 11$ 1-18 
 
      
None (e) Neu/H-2q/IL-12 Day 3       5/5    (100%) 36 15-59 
NK (f) Neu/H-2q/IL-12 Day 3    5/5    (100%) 41# 14-121 
1Days after the i.v. challenge with TUBO cells. 
Significance (Wilcoxon rank sum test): * vs b, p<0.01 at least; $ vs b, not significant; # vs e, not 
significant. 
 
 
The results reported above have already been published (Nanni et al., 
2007).  
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DISCUSSION 
The high preventive efficacy of the Triplex cell vaccine previously reported 
opened up the prospective of a future translation of the treatment to clinical 
patients. Early human trials will be necessarily performed in advanced cancer 
patients, in a therapeutic, rather than preventive set-up. The target of cancer 
therapeutic approaches could be an established primary tumor as well as 
metastasis formation. The Triplex cell vaccine activity was investigated, in this 
thesis, in a preclinical model against the development of experimental lung 
metastases. 
First of all, the vaccine ability was evaluated in BALBneuT mice, 
immunologically tolerant for the oncoantigen neu. The treatment was started 
seven days after the experimental metastasis induction, i.e. on sizeable and 
organized metastatic deposits to reinforce this preclinical model. This delay 
could correspond to some months of metastatic development in humans. The 
vaccine decreased the metastatic burden more than 87%. Such successful result 
was further improved by an earlier beginning of the treatment.  
The tolerance of BALBneuT immune system for the neu oncoantigen surely 
obstacles the complete eradication of lung metastases by Triplex vaccine. An 
indirect proof was obtained by the therapy of experimental metastases in 
nontolerant BALB/c mice since the Triplex vaccine cured almost all mice (> 
90%), starting the treatment at day 7, and all mice starting at day 1.  
The stronger therapeutic activity of the Triplex vaccine in nontolerant mice 
suggested that manipulation of peripheral tolerance should enhance 
antimetastatic efficacy in tolerant mice. Treg cells have been reported to 
suppress the immune response against tumors and decrease the efficacy of 
cancer vaccines (Ambrosino et al., 2006; Wei et al., 2008; Finn, 2008). The 
depletion of Treg cells in BALBneuT mice increased the activity of Triplex cell 
vaccine since, combining the two treatments, the therapeutic results were of the 
same order of magnitude as those obtained in nontolerant mice. 
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The therapeutic activity of Triplex vaccine is supported by various immune 
mechanisms: among them IFN-γ is the playmaker of the attack against the 
tumor as demonstrated by in vivo and in vitro results. Mice knockout for this 
cytokine were not significantly protected from lung metastases by Triplex 
vaccine. Moreover the spleen cells derived from vaccinated mice could produce 
IFN-γ and specific restimulation increased its production level. The key role of 
IFN-γ is closely related to a T helper response polarized to Th1 immunity. 
However, in vitro tests also showed a significant production of IL-4 in this 
system, proving that Th2 lymphocytes were activated as well. The importance 
of CD4+ cells was confirmed by in vivo studies in immunodepressed mice, by 
specific depletion of CD4+ cell population.  
High anti-neu antibody levels were produced by treated mice, but vaccinated 
antibody-deficient mice were still protected from lung metastases compared to 
untreated ones. These data are surprising because mammary cancer prevention 
by Triplex is completely dependent on antibody production (Nanni et al., 
2004), and shows that therapy of lung metastases does not depend on anti-neu 
antibodies. The lower therapeutic relevance of the antibody response in 
metastasis therapy could be explained considering that the time required for the 
vaccine to induce a strong secondary IgG response was of the same order of 
magnitude as that of metastasis growth. In the case of cancer prevention, on the 
contrary, a full-fledged antibody response could reach its upper plateau when 
fully neoplastic cells are not yet present in the mammary gland (Di Carlo et al., 
1999; Nanni et al., 2001).  
In cancer immunoprevention it was observed that the most relevant activity 
of IFN-γ was the induction of protective antibody responses because vaccine 
activity completely disappeared both in IFN-γ knockout mice, which no longer 
produced protective Ig isotypes, and in antibody-deficient mice, which, 
however, retained the capacity to produce IFN-γ (Nanni et al., 2004). In the 
therapeutic set-up mice lacking anti-HER-2/neu antibodies were protected from 
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metastatic development, thus other activities of IFN-γ played a more 
fundamental role than Ig class switch. 
Additional vaccine-induced actions were promoted by granulocytes and 
macrophages infiltrating tumor cell nests in the lungs, therefore the cure of lung 
metastases took advantage from the peculiar anatomic localization of these 
metastasis since local inflammatory responses in the lungs play a major role in 
the defense of host against foreign mechanisms (Di Carlo et al., 2001). 
On the whole, the Triplex vaccine is an effective treatment not only for the 
prevention of mammary carcinogenesis but also for the cure of 
micrometastases. The therapeutic activity of Triplex cell vaccine reported in 
this thesis is a promising result that opens up the possibility of early clinical 
testing in a therapeutic, rather than prophylactic, human context. 
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SECTION 3
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A DNA-TRIPLEX VACCINE FOR p53/neu DRIVEN 
CANCER SYNDROME 
 
INTRODUCTION 
 
Rationale of a DNA Triplex vaccine 
The good results of Triplex vaccine as cancer immunopreventive treatment 
are darkened by several limits. The difficulties to use an allogeneic cell vaccine 
administered lifelong in human patients are related to logistics (good 
manufacturing practice-certified cell culture facility, storage and distribution), 
eligibility (depending on patient’s histocompatibility profile) and safety. 
Although previous studies reported that all the three components of Triplex 
vaccine are necessary, it was never investigated if they are also sufficient. In 
fact Triplex cell vaccine likely includes other immune stimuli; some of these 
molecules could be undesirable and/or unnecessary. Since an optimized vaccine 
should avoid unnecessary immune stimulation, the so far used form of Triplex 
cell vaccine could be an obstacle for clinical translation. 
The need of easier, simpler and more controlled vaccine formulations could 
find an answer in DNA vaccines. The possibility to obtain a second-generation 
Triplex DNA vaccine was therefore investigated. 
 
DNA vaccines 
DNA vaccines are a promising strategy being simple to construct, produce 
and deliver. 
DNA vaccines consist of plasmids carrying specific expression cassettes 
coding for antigenic moieties. Tumor antigens coded for by DNA range from 
full-length or extracellular domain sequences, required to induce an antibody 
response, to short MHC class I- or II-binding peptides sequences, to optimize 
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induction of T-cell responses (Rice et al., 2008). Gene expression is mostly 
driven by the cytomegalovirus immediate early enhancer promoter (CMV IE-
EP) and its adjacent intron A sequence, which ensure high transcription 
efficiency. Other elements include a transcription termination signal and a 
prokaryotic antibiotic resistance gene (Draghia-Akli et al., 2008). An important 
component of the plasmid can be the presence of unmethylated CpG motifs 
which can stimulate the innate immunity by binding to Toll-like receptor 9 
(TLR9). The activated signaling cascade promotes the production of IFN-α, 
inflammatory cytokines such as IL-12, and chemokines. IFN-α induces a Th1 
response (Prud'homme, 2005). Further modifications are being explored to 
increase performance of vaccines such as the combination with 
immunostimulatory molecules: chemokines to attract antigen-presenting cells 
(APC), activating cytokines, co-stimulatory molecules, APC-targeting 
antibodies and molecules to manipulate antigen presentation and/or processing 
(Rice et al., 2008).  
DNA vaccines can be administered by intramuscular, dermal/epidermal, oral, 
pulmonary or other routes (Prud'homme, 2005). The most popular way of 
delivery is by intramuscular (i.m.) injection. Skeletal muscle is a good target 
tissue because it is characterized by post-mitotic muscle fibers and high 
vascularization, moreover muscles are easily accessible and the expression of 
the target gene is localized (Prud'homme et al., 2006). Transfected muscle cells 
can express antigen that can act as a target for immune effectors. For activation 
of T cells, antigen must be transferred to a “professional” antigen-presenting 
cells by cross-presentation; a small rate of DNA is also taken up directly by 
APC (Rice et al., 2008). 
DNA vaccination by i.m. route is not usually in large species as effective as 
in rodents. A major reason for the weak immune response obtained in large 
animals could be the volume of injection. This parameter is relevant for the 
production of an hydrostatic pressure which increases transfection and 
contributes to inflammation by causing a sufficient local damage. Scaling up 
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from a volume of injections able to induce strong immune responses in rodents, 
e.g. 50 µl/muscle in mice, to human subjects would be unacceptable (Rice et 
al., 2008). 
Several approaches were developed to increase plasmid delivery; among 
them, the most successful method is the electroporation. This strategy is based 
on an electrical stimulation of skeletal muscle with a pulse generator that is 
applied immediately after i.m. injection of DNA. The procedure increases 
antigen expression presumably by enhancing transfection efficiency thanks to 
the opening of cell membrane pores (Draghia-Akli et al., 2008). 
Electroporation is accompanied by a transient local tissue injury and 
inflammation that seem to be essential for effective response to DNA 
vaccination. The outcome is a dramatic increase of humoral and cellular 
immune responses (Fattori et al., 2002; Rice et al., 2008). 
At now, some DNA vaccines are already being evaluated in clinical trials, 
resulting well-tolerated also when combined to electroporation (Rice et al., 
2008). A pre-treatment with a local anesthetic is used to minimize the 
discomfort of the procedure (Draghia-Akli et al., 2008). 
 
HER-2/neu DNA vaccines 
DNA vaccines targeting HER-2/neu antigen produced good results in murine 
transgenic models (Pupa et al., 2005; Wei et al., 2008; Cho et al., 2008). 
Quaglino and colleagues (Quaglino et al., 2004) used, as DNA vaccine, a 
plasmid coding for the extracellular and transmembrane domains of the product 
of the HER-2/neu oncogene (pNeu) combined with electroporation. I.m. 
vaccination of BALBneuT mice started at the stage of multifocal in situ 
carcinomas (at 10 weeks of age) and was repeated for four vaccination courses 
(each course consisted of two administrations) with a 10-week interval between 
courses. Treated mice were maintained tumor free up to a year of age. This 
DNA vaccination eliminated existing mammary tumors without inducing 
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autoimmunity. Mice that also received multiple systemic administration of IL-
12 (starting at 7 weeks of age), were protected from tumor onset even when 
vaccination was started at 16 weeks of age, when mice already developed 
invasive carcinomas. Moreover only two vaccination courses (at 16 and 23 
weeks of age) were sufficient to arrest the tumor progression (Spadaro et al., 
2005).  
 
AIM 
This part of the work was aimed at developing and testing a Triplex-like 
DNA vaccine (named Tri-DNA) consisting of the combination of three 
plasmids, each carrying the extracellular and transmembrane portion of HER-
2/neu (pNeu), the murine IL-12 genes (pIL12) and the D region of the H-2q 
(pDq).  
The immune response elicited by Tri-DNA vaccine and its cancer preventive 
efficacy were compared to those of cell Triplex vaccine in BALBp53neu 
female mice, a model system more aggressive than BALBneuT female mice.  
For this study Tri-DNA and Triplex cell vaccine were administered 
according to short schedules which could likely allow to outline either better or 
worse effect of DNA vaccine versus cell vaccine.  
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RESULTS 
 
Plasmid validation 
The first step consisted in the demonstration of the ability of the individual 
plasmids to transfer and to give expression of the transgene carried.  
The activity of the plasmid pNeu was reported in previous studies in which 
this plasmid was used as a single DNA vaccine (Quaglino et al., 2004; 
Pannellini et al., 2006; Cho et al., 2008): i.m. injection and electroporation of 
pNeu induced anti-neu antibody responses in HER-2/neu transgenic mice. 
The plasmid carrying murine IL-12 genes was tested by analyzing the level 
of IL-12 and IFN-γ cytokines in the serum of mice treated with only pIL12. 
Specifically, a small group of mice received i.m. injections of pIL12 and 
electroporation with the same conditions chosen for vaccination experiments. 
Then mice were bled at several time points and the levels of IL-12 and IFN-γ 
was evidenced by ELISA test. An increase of serum IL-12 after plasmid 
injection and of IL-12-induced serum IFN-γ was found. The levels of these two 
cytokines were detectable for some days (Figure 9A). Serum IL-12 or IFN-γ 
levels were undetectable in untreated mice as well as in mice treated with 
empty pIRESneo vector (data not shown). 
To validate pDq, a MHC-negative cell line (B78H1) was transiently 
transfected with this plasmid, coding for H-2Dq. After 48 hours H-2Dq 
expression on cell membrane surface was observed by cytofluorometric 
analysis (Figure 9B). The ability of pDq to act as allogeneic MHC was verified 
through vaccination of BALB/c mice (H-2d haplotype). Sera of these mice were 
investigated for the presence of complement-dependent cytotoxic antibodies 
against H-2q or H-2d lymphocytes (obtained from FVB-NeuN#202 or BALB/c 
mice respectively). Vaccination with pDq was able to induce specific antibodies 
with complement-dependent cytotoxic activity towards H-2q lymphocytes 
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(Figure 9C). Therefore pDq plasmid can transfer H-2Dq expression and elicit a 
specific antibody response. 
 
Figure 9. Validation of pIL12 and pDq vectors. A, induction of serum IL-12 (closed circles) and 
IFN-γ (open triangles) after i.m. injection and electroporation of 50 µg of pIL12 (treatments 
indicated by arrows). Mean and standard error from 3 mice. B, cytofluorometric evaluation of 
H-2Dq expression in B78H1 cells 48 hours after transfection with pDq (bold profile). Dotted 
profile: untreated B78H1 cells. X-axis reports the fluorescence intensity (arbitrary units), Y-
axis reports the number of events. C, complement-dependent cytotoxic (CDC) activity against 
H-2q or H-2d lymphocytes by sera of H-2d mice subjected to i.m. injection and electroporation 
of 50 µg of pDq plasmid (closed bars, 2 mice) or untreated controls (open bars, 2 mice). 
Hatched bars: 28-14-8S positive control serum. Mean and standard error are shown.  
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Immunoprevention of cancer syndrome through DNA vaccines  
BALBp53neu female mice develop salivary gland carcinomas between 13-15 
weeks of age and mammary tumors around 19-20 weeks. These mice were 
treated with Tri-DNA vaccine or cellular Triplex vaccine to compare their 
effectiveness (Figure 10). The DNA vaccine schedule consisted of four i.m 
injections and electroporation at 5, 7, 12 and 14 weeks of age. Tri-DNA 
vaccine, referred to as pNeu+pIL12+pDq, was also compared to other DNA 
vaccines to evaluate the lack of the allogeneic MHC component (pNeu+pIL12) 
and of both adjuvants (pNeu). The cellular Triplex vaccine was administered in 
BALBp53neu female mice for only three 4-week cycles according to the Early 
schedule which was described in Section 1. Both DNA and cell vaccine 
stimulation started at 5 weeks of age and ended at 14 weeks of age. 
Mice were observed weekly, with recording of the occurrence of the two 
types of cancer typical of such model, salivary and mammary carcinomas. 
BALBp53neu females mice, either untreated (Croci et al., 2004) or subjected to 
mock vaccination and electroporation (Figure 10, dotted line) showed a fast and 
almost simultaneous occurrence of salivary and mammary cancers (with 
latencies of 13-15 weeks for the former -see also Figure 11A-11D- and slightly 
longer for the latter). Both cell Triplex vaccine and the three DNA vaccines 
delayed significantly the mammary and salivary tumor onset. All vaccines had 
a similar behavior in the prevention of mammary carcinomas moving the 
median latency from 19-20 to 45-55 weeks of age. For what concerns the 
salivary carcinogenesis, salivary cancers were fully prevented by Tri-DNA 
vaccine. Although cell Triplex vaccine was slightly less effective than Tri-DNA 
vaccine, three treatment cycles were sufficient to prevent almost completely 
from salivary tumors. Finally, DNA vaccines pNeu and pNeu+pIL12 showed a 
lower protective ability compared to the complete Tri-DNA vaccine even if 
with a borderline statistical significance (respectively p=0.074 and p=0.096, 
Mantel-Haenszel test).  
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Figure 10. Cancer immunopreventive activity of DNA vaccines and cell Triplex vaccine in 
BALBp53neu female mice (5-9 mice per group). Vaccination cycles are shown with arrows 
(DNA vaccines) or boxes (Triplex cell vaccine). Dotted line: mock-electroporated control mice. 
Significance of differences with Mantel-Haenszel test: any vaccine vs mock, p<0.05 at least 
(both salivary and mammary carcinoma); pNeu+pIL12+pDq vs pNeu+pIL12 or pNeu, p=0.074 
or p=0.096 respectively (salivary carcinoma only).  
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Morphological analysis 
Mice vaccinated with Tri-DNA showed normal salivary glands with well-
defined ducts and acini that were enclosed in delicate stromal tissue (Figure 
11E). On-going inflammatory aspects or inflammation effects (e.g. scars) were 
not detected. Neu expression was not found in salivary glands from Tri-DNA 
vaccinated mice (Figure 11F), although it was observed in both hyperplastic 
duct and acinic cells prior to vaccination (Figure 11B and 11D). On the other 
hand, Tri-DNA vaccinated mice showed several neu+mammary cancer nodules 
with inflammatory cells in their stroma (Figure 11G and 11H). 
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Figure 11. Histology (A, C, E and G) and immunohistochemistry (B, D, F and H) of salivary 
(A-F) and mammary glands (G-H) of BALBp53neu female mice. The salivary gland obtained 
from a 5 week-old untreated mouse (A) shows several foci of small duct hyperplasia (arrows) 
which are intensively positive for neu (B). The salivary gland of a 18 week-old untreated mouse 
is almost completely occupied by a scarcely differentiated neu+ carcinoma (C, D). The salivary 
gland obtained from a 38 week-old Tri-DNA vaccinated mouse is morphologically normal with 
well defined ducts and acini (E) constituted by cells without expression of neu (F) while the 
corresponding mammary tissue shows invasive carcinoma (G) with cells clearly expressing neu 
on membranes (H). A well vascolarised stroma (G and H, arrows) with inflammatory cells is 
present at the periphery of the mammary tumor. In F and H within the stroma some false 
positive cells with macrophage morphological features can be observed. 
 
 
Cytokine production  
Although Tri-DNA and cell Triplex vaccines showed similar preventive 
efficacy they could drive in different ways the cellular immune responses. The 
cytokine production by vaccinated lymphocytes can enlighten the immune 
mechanisms induced by the treatment. Spleen cells of vaccinated and untreated 
mice at the end of the first vaccination cycle were cultured alone (spontaneous 
production) or in the presence of proliferation-blocked cell lines able to 
specifically restimulate in vitro. These target cell lines were: mammary 
carcinoma neu negative allogeneic cells (Neuneg/H-2q), mammary carcinoma 
neu
+
 syngeneic cells (Neu/H-2d) and mammary carcinoma neu+ allogeneic cells 
(Neu/H-2q). Culture supernatants were collected and analyzed for an array of 
cytokines. 
Cell Triplex vaccine induced a very high production of IFN-γ already evident 
without in vitro restimulation, moreover induction of IL-4 together with other 
Th2 cytokines such as IL-5 and IL-10 was observed (Figure 12). Spleen cells 
derived from Tri-DNA vaccine group showed a significant IFN-γ production 
only upon the restimulation with cells presenting allogeneic MHC alone or 
combined with neu expression. This vaccine did not increase significantly the 
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level of Th2 cytokines. Spleen cells derived from mice treated with 
pNeu+pIL12 and pNeu alone as well as those from mock-electroporated control 
mice (data not shown) showed barely detectable spontaneous cytokine 
production levels. In vitro stimulation did not increase IFN-γ or IL-4. All 
vaccinations produced an increase of GM-CSF after restimulation while TNF-α 
level did not seem to be different among several treatments. 
The production of IFN-γ and IL-4 by CD4+ and CD8+ populations was also 
studied (Figure 13). CD4+ spleen cells of mice treated with cell Triplex vaccine 
secreted a high level of IFN-γ  both spontaneously and after restimulation. The 
Tri-DNA induced a more selective and reduced production of IFN-γ by CD4+ 
cells and only in presence of allogeneic MHC molecules alone or combined 
with neu antigen. Also the production of IFN-γ by CD8+ cells was specifically 
induced by these two stimuli for both Tri-DNA and cell Triplex (stimulated 
also by neu alone) vaccines. Finally IL-4 was revealed only in the supernatants 
of CD4+ spleen cells derived from Triplex cell vaccinated mice. The presence 
of allogeneic molecules in absence of neu antigen reduced the rate of IL-4. 
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Figure 12. Cytokine production by total unseparated spleen cells collected after the first 
vaccination cycle and cultured 6 days alone or in the presence of the indicated restimulator 
cells. Mean and standard error from 2-3 mice per group is shown.  
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Figure 13. Cytokine production by CD4+ or CD8+ spleen cells collected after the first 
vaccination cycle and cultured 6 days alone or in the presence of the indicated restimulator 
cells. No IL-4 production by CD8+ cells was observed (data not shown). Mean and standard 
error from 2-3 mice per group is shown. 
 
Humoral response  
Previous data obtained with cell Triplex vaccine suggested that anti-neu 
antibodies played a key role in the vaccine induced protection. Sera of mice 
treated with cell Triplex, Tri-DNA, pNeu and pNeu+pIL12 were investigated 
for the presence of these antibodies by ELISA assay (Figure 14A). Antibodies 
recognizing neu antigen were specifically detected in all vaccine groups. The 
main differences were found after the first vaccinations since all mice in the 
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Tri-DNA vaccine group (closed squares) already showed detectable levels of 
anti-neu antibodies, whereas sera of pNeu and pNeu+pIL12 DNA vaccines as 
well as cell Triplex vaccine revealed some late-responder mice. Then, the level 
of anti-neu antibodies reached at the end of the vaccination protocol was similar 
for all DNA vaccines, whereas the highest antibody levels were obtained with 
cell Triplex vaccine (open squares).  
The antibody response was detected also by cytofluorometric analysis testing 
the ability of sera from vaccinated mice to bind syngeneic or allogeneic neu+ 
cells (Neu/H-2d and Neu/H-2q cells respectively, Figure 14B and 14C). Kinetics 
and differences of induction of humoral reactivity were similar to those found 
with ELISA assay. Mock-electroporated control mice did not develop any 
humoral response, both when tested by ELISA assay and by cytofluorometric 
analysis (data not shown). The reactivity against Neu/H-2q cells observed with 
sera of groups including allogeneic MHC in vaccine formulation obviously 
comprises anti-histocompatibility antibodies. Anyway a minor contribution to 
binding is attributable to histocompatibility since such sera tested against a neu 
negative H-2Dq -expressing target cell had a very low binding activity (data not 
shown). In fact DNA vaccines lacking allogeneic MHC gene (pNeu+pIL12 and 
pNeu alone) could induce antibodies almost as effectively as the DNA vaccine 
including the H-2Dq gene. 
Finally mice sera were investigated to define the isotype profile of the 
antibodies binding syngeneic neu+ cells. The isotype profile showed that all  
vaccines induced comparable levels of IgG2a antibodies, but only cell Triplex 
vaccine caused a very high level of IgG3 antibodies, together with a slight 
increase in IgG1 antibodies (Figure 15). 
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Figure 14. Humoral response of BALBp53neu female mice vaccinated with the indicated DNA 
vaccines compared to cell Triplex vaccine. Vaccination cycles are shown with arrows (DNA 
vaccines) or boxes (cell Triplex vaccine). Data from 5-9 individual mice are shown in each 
panel. A, anti-neu antibodies, measured by ELISA assay on sera at 1:300 dilution. Dotted line: 
sensitivity of the test. Significance of differences between groups (non-parametric Wilcoxon 
test): pNeu+pIL12+pDq vs pNeu+pIL12 or pNeu at 7 wk (1 vaccination), p=0.06 and p=0.04, 
respectively; any DNA vaccine vs cell Triplex at 16 wk, p<0.05. B, cytofluorometric analysis of 
serum binding activity towards Neu/H-2d cells. Significance of differences between groups 
(non-parametric Wilcoxon test): pNeu+pIL12+pDq vs pNeu+pIL12 or pNeu at 7 wk, p<0.05; 
any DNA vaccine vs cell Triplex at 16 wk, p<0.01. C, cytofluorometric analysis of serum 
binding activity towards Neu/H-2q cells. Significance of differences between groups (non-
parametric Wilcoxon test): pNeu+pIL12+pDq vs pNeu at 7 wk, p<0.05; any DNA vaccine vs 
cell Triplex at 16 wk, p<0.01. 
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Figure 15. Analysis of antibody isotypes induced by DNA and cell Triplex vaccination. 
Normalized fluorescence intensity against Neu/H-2d cells by sera collected from 16-week old 
mice is shown. Mean and standard error from 5-9 mice per group. 
 
 
The results reported above have already been published (De Giovanni et 
al., 2009b). 
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DISCUSSION 
The perspective of a future translation of the Triplex vaccine to human 
patients drove the study of a new generation of Triplex DNA vaccine. The 
advantage of DNA vaccines for clinical use is closely related to fewer 
difficulties in vaccine production, greater flexibility and safety compared to 
cellular vaccines. 
The Triplex DNA (Tri-DNA) vaccine combines three plasmids coding for the 
extracellular and transmembrane portion of the rat activated HER-2/neu 
oncoantigen (pNeu), the murine IL-12 genes (pIL12) and the H-2Dq gene (pDq) 
respectively. The ability of the vaccine was tested on BALBp53neu female 
mice, knockout for a p53 allele and transgenic for the rat activated neu 
oncogene. The development of a cancer syndrome with early onset of salivary 
and mammary tumors gives a more aggressive preclinical cancer progression 
than in BALBneuT female mice. Therefore the study of vaccines in 
BALBp53neu mice can highlight positive and negative sides of the treatments. 
The aim of in vivo studies was to compare two “complete” treatments (with 
neu target antigen and both adjuvants stimuli), Tri-DNA and cell Triplex 
vaccines. Furthermore the contribution of the two adjuvants was tested through 
vaccination without plasmid coding for allogeneic MHC or with neu plasmid 
alone. A similar analysis of Triplex components had already been carried out 
on the cell vaccine in previous studies on BALBneuT mice (Nanni et al., 2001; 
De Giovanni et al., 2004) anyway these data are however not free from the 
possible influence of other cell components which can contribute to the 
protective ability of the vaccine. Thus the in vivo evaluation of Tri-DNA 
(pNeu+pIL12+pDq) proved that the presence of only these three stimuli is 
sufficient for the prevention of early and aggressive carcinogenesis in 
BALBp53neu female mice. 
Tri-DNA and Triplex cell vaccines induced a similar protective response in 
BALBp53neu mice. The development of mammary carcinoma was delayed by 
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both treatments moving the median latency from 19-20 to 45-55 weeks of age; 
the lacking of IL-12 and/or allogeneic MHC molecule Dq did not significantly 
reduce the protection from mammary cancer. The early onset of salivary tumors 
was completely prevented at more than one year of age by Tri-DNA and almost 
completely by cell Triplex vaccine. The absence of one or both adjuvants 
reduced the efficacy of the prevention from salivary tumors. Although the two 
different forms of Triplex vaccine achieved similar results, the number of 
requested injections is surely lower for DNA vaccine and so in a translational 
perspective less stressing for patients. 
The study of immune responses induced by cell Triplex vaccine revealed a 
powerful Th1 stimulation proved by the high production of IFN-γ, both 
spontaneous, only for CD4+ cells, and after restimulation. Moreover the 
presence of relevant levels of IL-4, IL-5 and IL-10 suggested that also Th2 
immune response was stimulated by cell Triplex vaccine. In particular the 
restimulation with neu+ syngeneic cells increased the rate of IL-4. On the 
contrary, Tri-DNA vaccine sustained a highly restricted Th1 response: IFN-γ 
secretion was detected only after restimulation, mainly by the allorecognition, 
and the major producers were CD8+ cells.  
All studied vaccines induced antibody production. In detail, the various DNA 
vaccines did not reach remarkably different antibody levels, but the presence of 
adjuvants in the Tri-DNA vaccine seems to confer a faster and more 
homogenous response. In the first cycle also cell Triplex vaccine did not induce 
similar levels of anti-neu antibodies as showed by few late-responder mice 
although at the end of treatment cell Triplex vaccine group reached 
significantly higher levels of antibodies both binding to syngeneic and  binding 
to allogeneic neu+ cells. 
The isotypes analysis of antibodies binding syngeneic neu+ cells confirmed 
the importance of IgG2a for the activity of all vaccines (Nanni et al., 2001; 
Nanni et al., 2004). Cell Triplex vaccine induced higher IgG1 and IgG3, levels 
compared to DNA vaccines. 
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Therefore Tri-DNA vaccine was as effective as cell Triplex vaccine. The 
three stimuli of the Triplex are not only necessary but also sufficient to 
delay/prevent carcinogenesis in BALBp53neu female mice.  
Moreover Tri-DNA induced a more restricted immunostimulation thanks to a 
controlled antigenicity, in comparison with the cell Triplex vaccine. In fact a 
cellular vaccine in principle could carry a portfolio of immune stimuli, other 
than desired, whereas this Tri-DNA vaccine only carries the three genes 
chosen. In particular an allogeneic cell vaccine carries multiple different MHC 
genes. In Tri-DNA vaccine a single MHC gene was used as adjuvant instead of 
a complete haplotype. The MHC gene chosen, H-2Dq, has about 88% 
homology with the corresponding MHC gene of the host d haplotype, 
nevertheless it gave a good stimulation as well, as found by the high IFN-γ 
response by allo-restimulated spleen cells. Such IFN-γ induction could take 
place even in vivo after each vaccination cycle, contributing to the effectiveness 
of the vaccine. 
Monoantigenic anti-neu electroporated DNA vaccines have been reported to 
confer protection against carcinogenesis driven by neu alone (Quaglino et al., 
2004). Carcinogenesis induced by the combination of neu and p53 knockout is 
much more aggressive and hard to prevent (Croci et al., 2004; Pannellini et al., 
2006). Confirming these data, this work proved that Tri-DNA vaccine was 
more effective than pNeu vaccine in maintaining all mice free from salivary 
tumors. The main reason of this difference can be found in the faster and 
homogeneous rise of antibodies induced combining pNeu with two adjuvants 
plasmids. So the presence of adjuvants can reduce the individual variability of 
the antibody response induced by DNA vaccines (Cipriani et al., 2008) and 
found in the early stage of vaccination. Since immunoprevention in neu 
transgenic models was reported to be related both to the individual antibody 
level (Cipriani et al., 2008) and to the precociousness of the response induced 
((Croci et al., 2004; Pannellini et al., 2006); our unpublished data, see Section 
1), a more homogeneous response induced by Tri-DNA vaccine is desirable. 
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Differently from salivary carcinogenesis, however, no superior effect by Tri-
DNA vaccine was observed for mammary carcinogenesis. Probably, since the 
onset of salivary carcinoma occurs earlier than mammary carcinoma, an early 
and necessarily high response is sufficient to arrest definitively the salivary 
carcinogenesis. On the contrary the arrest of mammary tumor onset requires a 
more exacting control. In fact, as previously reported in Section 1, a reduction 
of anti-neu antibodies, even after a long time of repeated vaccinations, could be 
sufficient to allow mammary tissue progressing into tumor. 
Tri-DNA vaccine showed a restricted immune response and it is a good 
attribute for a immunopreventive cancer vaccine. Of note is the absence of 
IgG3 (corresponding to human IgG2). Murine IgG3 antibodies do not bind 
FcR, but can activate the complement system through Fc-Fc interactions 
(Getahun and Heyman, 2006). Some data on the involvement of murine IgG3 
in autoimmunity have also been reported (Baudino et al., 2006). Autoimmunity 
could be a serious side effect of cancer immunoprevention (Wei et al., 2008), 
since cancer antigens, included HER-2, can be expressed on normal tissues. 
However in this study, such as in others (Garcia-Hernandez et al., 2008), it was 
not observed any sign of autoimmunity in all vaccinated mice suggesting that 
the high level of IgG3 antibodies elicited by cell Triplex vaccine could be 
dispensable but not detrimental to mice health. 
In conclusion, DNA vaccines, and in particular Triplex DNA vaccine, 
resulted as effective as cell Triplex vaccine, exploiting a more restricted 
immune stimulation.  
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CONCLUSIONS 
 
This thesis deals with the study of three preclinical conditions applying to the 
Triplex vaccine. 
The preclinical efficacy of Triplex cell vaccine depends on the schedule of 
treatment. The minimal number of administrations and their distribution are not 
well defined yet. Anyway, the achieved data suggest that vaccine 
administration should be frequent in the first weeks of treatment so that a high 
level of anti-vaccine antibodies can be reached as soon as possible. Moreover 
long-life periodic boosts are thought to be necessary so that antibody 
production is kept high. The research for new optimal protocols will go on and 
first of all in silico model shall be improved in order to be closer to in vivo 
conditions. 
A second important result was the demonstration of the ability of Triplex cell 
vaccine to cure experimental lung micrometastases. This successful result 
opens up the possibility of early clinical testing in a therapeutic, rather than 
prophylactic, human context. New vaccination schedules, predicted by in silico 
model of metastatic development, may be tested in order to obtain a higher 
efficacy of the vaccine  
Finally the study of a new formulation of Triplex cell vaccine, i.e. Triplex 
DNA vaccine, showed that DNA vaccine is as effective as cell vaccine, but 
inducing a more restricted immune stimulation. The combination of multiple 
plasmids and the high efficacy obtained through electoporation makes the 
system very handful and flexible. This novel strategy may be effective in the 
prevention of HER-2 expressing tumors in humans at high risk. This class, even 
if it is not yet well defined, could include healthy people who have a specific 
genetic risk of cancer, who have been exposed to an exogenous carcinogen or 
who bear multifocal pre-neoplastic lesions. Future studies will include the 
evaluation of Triplex DNA vaccine in a preclinical therapeutic setting. 
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Other investigations, not reported in this thesis, took into account further 
aspects potentially relevant for cancer immunoprevention, such as combination 
with current chemopreventive approaches (De Giovanni et al., 2009a), antigen 
presentation (Croci et al., 2007) and the possibility to extend active 
immunological strategies to prevention of other tumors, such as prostate cancer 
(De Giovanni et al., 2007). 
In conclusion, cancer immunoprevention is becoming an attractive goal, 
although studies have been limited so far to preclinical models. A deeper 
analysis of such models, with combination of theoretical and technical 
advancement, the identification of high-risk patients and of suitable target 
antigens and adjuvants could pave the way to clinical translation in next 
decades. 
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MATERIALS AND METHODS 
 
MICE 
BALB/cAnNCrlBR (BALB/c) mice were purchased from Charles River 
Italy. BALBneuT mice (H-2d haplotype) overexpressing the activated rat HER-
2/neu oncogene driven by the mouse mammary tumor virus long terminal 
repeats (MMTV LTR), IFN-γ gene knockout BALB/c mice, and µMT mice 
(knockout for the immunoglobulin µ chain gene) were bred, maintained, and 
genetically screened as reported (Boggio et al., 1998; Nanni et al., 2004). 
BALBp53neu mice, knockout for the p53 oncosuppressor gene and transgenic 
for the activated rat HER-2/neu oncogene driven by the MMTV LTR, were 
bred, maintained, and genetically screened as reported (Nanni et al., 2003; 
Croci et al., 2004). Rag2-/-;γc-/- breeders were kindly given by the Central 
Institute for Experimental Animals (Kawasaki, Japan); then mice were bred in 
the animal facilities of the Cancer Research Section of the Experimental 
Pathology Department under sterile conditions. Experiments were authorized 
by the institutional review board of the University of Bologna and done 
according to Italian and European guidelines. 
Individually tagged virgin female mice of specific ages were used: mice of 6 
weeks of age for experiments reported in Section 1, mice of 6-9 weeks of age 
for experiments reported in Section 2 and mice of 5 weeks of age for 
experiments reported in Section 3.  
 
CELL LINES 
Neu+ TT12.E2 cells (in this thesis referred to as Neu/H-2q cells) and neu 
negative N202.1E cells (in this thesis referred to as Neuneg/H-2q cells) derived 
from mammary carcinomas arisen in FVB-NeuN#202 mice (H-2q haplotype), 
transgenic for the rat neu proto-oncogene (Nanni et al., 2000). IL-12 engineered 
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TT12.E2 cells (here referred to as Neu/H-2q/IL12) were obtained and described 
previously (De Giovanni et al., 2004).  
Neu+ TUBO cells (here referred to as Neu/H-2d cells) derived from a 
mammary carcinoma arisen in BALBneuT mouse (Rovero et al., 2000). 
Cells were cultured in DMEM supplemented with 20% fetal bovine serum 
(FBS; Invitrogen, Milan, Italy) at 37°C in a humidified 5% CO2 atmosphere. 
 
PLASMIDS 
Plasmid pcDNA3 coding for a transmembrane-extracellular domain fragment 
of rat HER-2/neu (in this work referred to as pNeu) has been described 
previously (Quaglino et al., 2004). 
Plasmid coding for both murine IL-12 genes (pIL12) was bicistronic pIL12-
IRES1neo (De Giovanni et al., 2004; Faggioli et al., 2008); it was able to 
induce a high IL-12 expression level when used to obtain stable IL-12 
engineered cells (De Giovanni et al., 2004). In order to evaluate pIL12 ability 
to give IL-12 expression in vivo, the plasmid was injected i.m. (50 µg) and then 
the muscle was electroporated (see below for conditions). Empty vector 
pIRES1neo was used under the same experimental conditions. Sera of treated 
mice were collected at different time points and investigated for the presence of 
IL-12 and IFN-γ by ELISA assays (R&D Systems, Minneapolis, MN).  
In order to obtain a plasmid coding for an allogeneic MHC gene, the H-2Dq 
gene was choosen. The H-2q haplotype was the same carried by the Triplex cell 
vaccine (H-2q, FVB/N strain). The construction of pDq was carried out through 
the collaboration with Dr. Silvano Ferrini (National Institute for Cancer 
Research, Genoa, Italy). The H-2Dq cDNA was cloned from different sources 
(lymphocytes and tumor cells). Briefly, cells were lysed in Trizol (Invitrogen, 
Milan, Italy) and total RNA was isolated using the RNAeasy system (Qiagen, 
Chatsworth, CA). The open reading frame of H-2Dq was amplified by RT-PCR 
from total RNA using the following primers: 
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5’CGATGGCTCCGCGCACGCTGCTC3’(forward) 
5’CAGTCCAGGCAGCTGTCTTCACGC3’(reverse)  
H-2Dq cDNA was cloned in the PCR2.1 vector using the TOPO-TA cloning 
system (Invitrogen), sequenced and then subcloned into the pcDNA3 
expression plasmid (Invitrogen): such plasmid will be hereafter referred to as 
pDq. Sequencing of different H-2Dq cDNA clones obtained showed an almost 
complete homology with a reported Dq sequence (Pullen et al., 1992), with 
only two mismatches leading to aminoacid changes (CAG/AGG at codon 69 
leading to a Q to R aminoacidic change, and CGC/GCC at codon 104, leading 
to an A to R change). Due to the consistency of these sequences in different 
clones, mismatches can be interpreted either as mistakes in the previously 
published sequence (Pullen et al., 1992) or as substrain variations. In order to 
evaluate the the ability of pDq to transfer H-2Dq expression a variant of B16 
melanoma (B78H1) was transfected with pDq (see “Gene Transfection"); 
moreover sera of mice treated with pDq were investigated for the presence of 
anti-H-2q antibodies able to induce complement dependent cytotoxicity (see 
“Complement dependent cytotoxicity”). 
 
Gene transfection 
B78H1 is a variant of B16 melanoma. This cell line is a very good 
transfection recipient and does not express MHC molecules (Graf, Jr. et al., 
1984; De Giovanni et al., 1991). B78H1 cells were seeded at the concentration 
of 0.25x106 cells/well in 6-well plates (Falcon, Oxnard, USA) and let to attach 
for 24 hours. Then pDq (2 µg/well) was transfected using Lipofectamine 2000 
(Invitrogen, Milan, Italy) at 1:2.5 ratio (DNA µg: Lipofectamine µl) according 
to the manufacturer’s protocol. Two days after transfection H-2Dq expression 
was evaluated on harvested cells, through indirect immunofluorescence and 
flow cytometry by the monoclonal antibody 28-14-8S (Ozato et al., 1982) 
(Cedarlane, Hornby, Canada). 
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VACCINATIONS AND OTHER MICE TREATMENTS 
 
DNA vaccines and treatment protocol 
Plasmid large-scale preparations were set up and purified using Endofree 
Qiagen Plasmid-Giga kits (Qiagen, Chatsworth, CA). DNA was precipitated, 
dissolved in water at a concentration of 3-5 mg/ml, and stored in monodose 
aliquots at -20°C for use in immunization protocols. For Tri-DNA vaccine, 50 
µg of each plasmid were mixed together and diluted to a final volume of 40 µl 
per mouse in 0.9% of NaCl and 6 mg/ml polyglutamate (final concentrations). 
Groups treated with combination of two plasmids or with pNeu alone received 
50 µg of each plasmid. Anesthetized mice received the injection of DNA 
vaccine into the tibial muscles (20 µl each muscle) through a 28-gauge needle 
syringe and immediately thereafter were subjected to electroporation, 
consisting of two square-wave 25 ms, 375 V/cm pulses generated by a T830 
electroporator (BTX, San Diego,CA). Mice received four vaccinations (5, 7, 12 
and 14 weeks of age). Control group received mock vaccinations as above but 
lacking plasmids. Mice were monitored weekly for mammary or salivary tumor 
onset. 
 
Cell vaccines 
The Triplex cell vaccine consisted in neu+ IL-12-engineered allogeneic 
mammary carcinoma cells (Neu/H-2q/IL12). The other two used cell vaccines 
are based on neu+ TT12.E2 cells (Neu/H-2q) and neu+ TUBO cells (Neu/H-2d 
cells). Before the vaccination, cells were treated with 40 µg/ml of mitomycin C 
(MitC; Sigma-Aldrich) to block cell proliferation. The evaluation of the surface 
expression of HER-2/neu and class I H-2q and H-2d molecules were performed 
as previously reported (Nanni et al., 2000; Nanni et al., 2001). Each treatment 
consisted in i.p. vaccination with 2x106 mitomycin C-treated cells in 0.4 ml 
PBS. Untreated mice received only 0.4 ml PBS 
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Prophylactic vaccination protocols 
In BALBneuT female mice all vaccination protocols started at 6 weeks of 
age.  
For Chronic-63 and the Early schedules, the vaccination protocol consisted 
of 4-week cycles: in the first 2 weeks, mice received four twice-weekly i.p. 
vaccinations followed by 2 weeks of rest. Chronic-63 protocol consisted of 15 
vaccination cycles so that mice received in all 60 vaccine doses and the last 
treatment was administered at the 63rd week of age. Early protocol consisted in 
only three vaccination cycles, thus the last vaccine administration was at 15 
weeks of age. 
Heuristic schedule consisted of light vaccination cycles: in the first 2 weeks, 
mice received two once-weekly i.p. vaccinations followed by 2 weeks of rest. 
This light vaccination cycle was repeated 15 times and mice received the last 
injection at 63 weeks of age. 
The Genetic protocol consisted in 32 vaccinations irregularly spaced over the 
time, from 6th weeks to 55th week of age. Considering the day 0 as the first 
vaccination day, mice were treated at days: 0, 3, 7, 24, 49, 56, 59, 66, 80, 84, 
91, 94, 105, 126, 133, 140, 143, 161, 171, 178, 199, 210, 231, 245, 269, 273, 
287, 301, 311, 322, 336, 343. 
BALBneuT mice, untreated or treated according to the Chronic-63, the Early, 
the Heuristic and the Genetic protocols, were bled every four weeks starting 
from the 9th weeks of age. Mice were monitored weekly for mammary tumor 
onset. 
BALBp53neu mice were treated according to a short protocol consisting in 
three vaccination cycles, as for the Early schedule. The vaccination started at 5 
weeks of age. Mice were monitored weekly for mammary or salivary tumor 
onset. 
 96 
In silico research of optimizing vaccination protocols for Triplex cell vaccine 
were kindly performed by the group of Prof. Santo Motta (University of 
Catania, Catania, Italy). 
 
Lung metastases and therapeutic vaccination  
For the induction of lung micrometastases, mice received i.v. 2.5x104  
Neu/H-2d cells. Mice were sacrificed 33 days after cell injection and subjected 
to an accurate necropsy. Lungs were stained with black India ink to better 
outline metastases and fixed in Fekete’s solution. Lung metastases were 
counted using a dissection microscope.  
Therapeutic vaccination started 1 or 7 days after metastasis induction. 
Schedule included two weekly administrations of cell vaccines (prepared as 
described above) repeated until sacrifice. Control groups included untreated 
mice and mice treated twice weekly with 100 ng/mouse of recombinant IL-12 
(kindly provided by Dr. S. Wolf, Genetics Institute, Andover, MA). 
 
In vivo cell depletions 
All depletion studies were done according to previously standardized 
protocols (Comes et al., 2006). T-cell depletion studies were performed by i.p. 
injection of anti-CD8 (2.43), anti-CD4 (GK1.5), or anti-CD25 (PC61) rat 
monoclonal antibodies (mAb), all from the American Type Culture Collection. 
All mAbs were first administered i.p. 24 hours after micrometastasis induction 
(i.e., 6 hours before the first vaccination). Treatment with anti-CD4 and anti-
CD8 mAbs was then repeated 24 hours after the first vaccination and 6 hours 
before the second, third, fourth, sixth, and eighth vaccination. The anti-CD25 
treatment was repeated 6 hours before the fifth vaccination. The mAb dosages 
were 200 µg/mouse (anti-CD8) or 500 µg/mouse (anti-CD4 and anti-CD25). 
For natural killer (NK) depletion, mice received i.v. 0.4 ml of a 1:30 dilution of 
anti-asialo GM1 antiserum (Wako) 48 hours after micrometastasis induction 
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(24 hours before the first vaccination); this protocol was found to avoid well-
known effects of NK depletion on metastatic seeding. 
 
IMMUNE RESPONSES 
 
Complement dependent cytotoxicity (CDC) 
BALB/c mice (H-2d) were vaccinated at 5 and 7 weeks of age by i.m. injection 
of pDq plasmid into the tibial muscles (25 µg in 20 µl each muscle) followed 
by electroporation (with same protocol reported above for DNA vaccination). A 
week after the second injection, pDq-vaccinated mice were bled and serum 
stored at -80°C. Aliquots of 0.5 x 106 lymphocytes, collected from BALB/c (H-
2d) and FVB-NeuN#202 (H-2q) mice, were resuspended in RPMI + 5% FBS 
containing sera from pDq vaccinated and from untreated BALB/c mice (1:10 
dilution in a final volume of 0.5 ml) and incubated for 30 minutes in ice. 
Baseline control in RPMI + 5% FBS medium and positive control, consisting in 
28-14-8s monoclonal antibody (recognizing both H-2q and H-2d epitopes) at 
1:10 dilution, were run in parallel. Lymphocytes were then washed once with 
PBS and incubated with 1:10 dilution of rabbit complement (Cedarlane 
Laboratories Ltd., Ontario, Canada) for 30 minutes in ice. Then lymphocytes 
were washed again, resuspended in RPMI + 5% FBS and cell number and 
viability determined by erythrosin dye exclusion test. Percent of cytotoxicity 
was calculated as: 100 – (cell yield in complement-contaning RPMI + 5% 
FBS/cell yield with serum)*100. 
 
Mixed lymphocyte-tumor cell cultures (MLTC) 
Spleens were collected from treated and control mice, and single cell 
suspensions were prepared, washed in PBS, and resuspended in RPMI 1640 
supplemented with 10% FBS. Total spleen mononuclear cells, or 
subpopulations (CD4+ or CD8+) purified by magnetic sorting (Miltenyi Biotec, 
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Bergisch Gladbach, Germany), were cultured (5x105 cells/ml) for 6 days at 
37°C alone or in the presence of proliferation-blocked restimulator cells (5x104 
cells/ml) in RPMI 1640 supplemented with 10% fetal bovine serum and with 20 
units/ml of recombinant IL-2. The ratio between lymphocytes and tumor cells 
was 10:1. Culture supernatants were collected and investigated for the 
production of murine IL-4 and IFN-γ  by ELISA assays (Endogen, Woburn, 
MA). Moreover, for what concerns experiments in BALBp53neu mice, some 
supernatants were further evaluated in order to define simultaneously the 
concentrations of IL-4, IL-5, IL-10, IL-12 (p70), GM-CSF, IFN-γ and TNF-α 
using the Bio-Plex 200 Suspension Array System (Bio-Rad, Milan, Italy). A 
commercially available premixed multiplex cytokine set was used (Mouse 
Cytokine Th1/Th2 panel) following manufacturer’s instructions and using a 
high sensitivity setting. Briefly, 50 µl of supernatants and serial dilutions of the 
cytokine standards were incubated at room temperature for 30 minutes with a 
mix of different fluorescently dyed beads conjugated with monoclonal 
antibodies specific for the various cytokines. Afterwards samples were 
incubated for 30 minutes with 25 µl of detection antibody then with 50 µl of 
streptavidinphycoerythrin (PE) for 10 minutes. Each step was followed by 3 
washings. Finally, samples were resuspended in 125 µl assay buffer and 
analysed into the Bio-Plex reader. 50 µl volume was sampled from each well 
and the PE-fluorescent signal of a minimum of 100 beads per cytokine type was 
evaluated. Bead doublets were excluded from analysis. Data were elaborated 
with the Bio-Plex Manager Software 5.0. Extrapolating PE-fluorescent signals 
to a standard curve allowed quantitation of each cytokine in the samples. 
Experimental range of detection of the various cytokines were the following: 
IL-4, 2100-0.2 pg/ml; IL-5, 500-0.1 pg/ml; IL-10, 1100-1 pg/ml; IL-12, 1100-1 
pg/ml; GM-CSF, 500-2 pg/ml; IFN-γ, 1400-0.3 pg/ml; TNF-α, 3700-3 pg/ml. 
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Cell-mediated cytotoxicity  
Cell-mediated cytotoxicity assays were kindly performed in the Laboratory 
of Dr. Silvano Ferrini (National Institute for Cancer Research, Genoa, Italy). 
Although the candidate did not carry out the morphological analysis, methods 
were reported below for an exhaustive description of the work. 
Spleen mononuclear cells of BALBneuT mice which have completed the 
treatment were restimulated by coculture at a 50:1 ratio with proliferation-
blocked Neu/H-2d cells for 6 days in RPMI 1640 supplemented with 10% fetal 
bovine serum and with 20 units/ml of recombinant IL-2. The ability of 
restimulated lymphoblasts to lyse Neu/H-2d or Neu/H-2q tumor cells was 
evaluated by a standard 51Cr release assay, and the percentage of lysis was 
calculated as described (Ferrini et al., 1985; Di Carlo et al., 2000). 
 
Antibody response 
Mice were routinely bled from a tail vein and sera were stored frozen at  
-80°C. The production of specific antibodies was then studied both by ELISA 
assay and/or by indirect immunofluorescence of syngeneic and/or allogeneic 
neu
+
 cells. 
ELISA assay to detect antibodies recognizing rat HER-2 was performed in 
Maxisorp NUNC 96-well microplates as reported (Cipriani et al., 2008). Plates 
coated with rat neu (kindly provided by Dr. Aurisicchio, IRBM, Rome) were 
incubated overnight with sera at 1:300 dilution, washed, incubated with goat 
antimouse IgG alkaline phosphatase-conjugated antibody (Sigma-Aldrich, St. 
Louis, MO) for 30 minutes at room temperature, washed again and developed 
with p-Nytrophenyl phosphate (Sigma). A standard curve with anti-c-
ErbB2/Neu mouse monoclonal antibody (clone 7.16.4, Calbiochem) was run in 
parallel (0.10-250 ng/ml).  
For immunofluorescence studies, Neu/H-2d and Neu/H-2q cells were 
incubated with sera at 1:65 dilution for 30 minutes in ice, then washed and 
incubated with an AlexaFluor 488 F(ab’)2 fragment of goat anti-mouse IgG (H-
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L) chains antibody (Molecular Probes, Eugene, OR) to evaluate total 
immunoglobuling binding.  
For isotype analysis, the following secondary FITC-conjugated mAbs were 
used (BD Pharmingen): anti-mouse IgG1 clone A85-1, anti-mouse IgG2a clone 
R19-15, anti-mouse IgG2b clone R12-3, anti-mouse IgG3 clone R40-82. 
Cytofluorometric analysis was performed through a FACScan flow cytometer 
(Becton Dickinson, Mountain View, CA).  
Rat HER2/neu expression of target cells was evaluated in each set of 
experiments with anti-c-ErbB2/Neu mouse monoclonal antibody. Data from 
each sample were normalized over target cells day expression. 
 
MORPHOLOGICAL ANALYSIS 
All morphological analysis were kindly performed in the Laboratory of Prof. 
Piero Musiani (Aging Research Center, Chieti, Italy). Although the candidate 
did not carry out the morphological analysis, methods were reported below for 
an exhaustive description of the work. 
 
Therapeutic vaccination: morphological analysis of lungs  
Groups of three mice were killed at 7, 14, 21, and 30 days after cell injection. 
To optimize the detection of microscopic metastases and to ensure systematic 
uniform and random sampling, lungs were cut transversally to the trachea into 
2.0-mm-thick parallel slabs with a random position of the first cut in the first 
2.0 mm of the lung, resulting in five to eight slabs per lung. The slabs were then 
embedded cut surface down. Tissue samples were processed as described 
previously (Ambrosino et al., 2006) for histologic evaluation.  
For immunohistochemistry, pyridoxal phosphate–fixed tissues were 
embedded in OCT and acetone-fixed cryostat sections were incubated for 60 
minutes with the following: anti-c-ErbB2/HER-2; anti-proliferating cell nuclear 
antigen (clone PC10; DakoCytomation); anti-CD4 (Chemicon International); 
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anti-CD8 (Oxford Biotechnology); anti-Gr1, a cell surface protein mainly 
expressed by granulocytes (clone RB68C5); anti-CD45R/B220, a subset of 
mouse CD45 isoforms predominantly expressed on B lymphocytes; anti-CD11b 
mainly expressed on monocytes-macrophages (BD Pharmingen); anti-Foxp3, 
nuclear transcription factor specific for regulatory T cells (Treg; clone 
MF333F, Alexis Italia); and a mix of anti-endothelial cell (CD31, Chemicon 
International; CD31, clone MEC13.3, and CD105/endoglin, clone MJ7/18, BD 
Pharmingen) antibodies. After washing, sections were overlaid with 
biotinylated goat anti-rat and antirabbit Ig (Vector Laboratories) for 30 minutes. 
Unbound Ig was removed by washing, and slides were incubated with avidin-
biotin complex/alkaline phosphatase (DakoCytomation).  
For immunofluorescence to detect p185 expression, Alexa Fluor 488–
conjugated secondary antibodies were used. 
For electron microscopy, lung lobes were fixed for 4 h in 2.5% 
glutaraldehyde in 0.2 mol/L HEPES buffer (pH 7.4) and processed as reported 
(De Giovanni et al., 2004). 
 
Comparison between Triplex DNA and cell vaccines in 
BALBp53neu: histology and immunohistochemistry 
For histologic evaluation, tissue samples were fixed in 10% neutral-buffered 
formalin, embedded in paraffin, sectioned at 4 µm, and stained with H&E. For 
immunohistochemistry, paraffin-embedded sections were immunostained with 
anti-c-erbB-2 (Dako, Milan, Italy). After washing, sections were overlaid with 
biotinylated anti-rabbit Ig (Jackson ImmunoResearch Europe, Suffolk, UK) for 
30 minutes. Unbound Ig was removed by washing, and slides were incubated 
with ready to use peroxidase streptavidin (Lab Vision, Bio-Optica Milan, Italy) 
and diaminobenzidine (Dako). 
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